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ABSTRACT
Novel therapeutic strategies for Alzheimer’s disease;
Target Toll-like receptor signaling and a multi-target approach
by
Giovanni Oliveros

Advisor: Dr. Maria E. Figueiredo-Pereira

Alzheimer’s disease (AD) is multifactorial, and its hallmarks include the formation of
amyloid-beta (Ab) plaques and neurofibrillary tau tangles, accompanied by an increase in glial cell
activation, culminating in neurodegeneration, chronic neuroinflammation, and cognitive decline
in human patients. AD will cost the United States over $300 million this year alone and is projected
to cost over $1 trillion by 2050, AD is a serious concern for the aging population, and efforts need
to be redirected towards more effective therapeutic intervention strategies. Drugs aimed at halting
AD progression have so far proven unsuccessful due to the development of pharmaceuticals that
target one aspect of the pathology while ignoring the others.
Investigators invested resources towards developing animal models that mimic human AD
progression. However, most of the current animal models do not capture all hallmarks of AD. For
example, the 5X FAD mouse model does not develop neurofibrillary tau tangles, while the 3X TgAD mouse model does not exhibit synaptic loss. Efforts should be focused to generating animal
that more accurately reflect disease progression and include the most significant risk factor, which
is aging, along with the other hallmarks. The goal would be to translate the results of obtained with
animal models to human therapeutic interventions.
iv

Another problem investigators face is the diagnosis and treatment timeline. Patients are
diagnosed when they already exhibit cognitive impairment, and by this time they have moderate
AD and significant neurodegeneration. At this stage it is too late for currently available
pharmaceuticals to have significant effects on halting disease progression. Thus it is important, to
identify early AD biomarkers that are significantly altered in AD patients prior to the development
of the plaques, tangles, and cognitive impairment so that therapeutics act more efficiently.
Considering the aforementioned problems with current AD research approaches, the
overall goal of my studies was to investigate the effects of using novel early therapeutic
interventions that target neuroinflammation, or a multitarget approach to mitigate AD progression.
My hypothesis was that (1) targeting neuroinflammation with ibudilast (IBU) or (2) using
a combined treatment with diazoxide (DZ) and dibenzoylmethane (DIB), will effectively slow
down the progression of AD. IBU is a multi-target drug that is a non-selective phosphodiesterase
inhibitor, a Toll-like receptor 4 (TLR4) antagonist, and is predicted (in-silico) to inhibit off-target
kinases, such as interleukin-1 receptor associated kinase 1 (IRAK1). DZ is a potassium channel
activator and DIB restores eIF2B activity, thus reversing stress-induced translational depression.
To test my hypothesis in vivo, I used the transgenic Tg-AD Fisher 344 rat model of AD. These
rats (Tg-AD) develop multiple hallmarks of AD including Ab plaques, tau tangles, neuronal loss,
neuroinflammation, and cognitive deficits in an age-dependent manner that is comparable to
human AD. My studies included mainly 11-month-old rats, because at this age, the Tg-AD rats are
mainly in the moderate AD stage (goal 1). Some of my studies (goal 3) also used rats at 4-months
of age to be able to compare the 4-month pre-pathology stage with the 11-month moderate
pathology stage.

v

Goal 1: Determine the effects of ibudilast, which alters Toll-like receptor signaling, on AD
pathology in a transgenic rat model of AD (Chapter 2).
I found that chronic ibudilast (IBU) treatment in Tg-AD rats slowed the development of
AD pathology, such as Ab plaques and neurofibrillary tau tangles in the hippocampal dentate gyrus
(DG) region. IBU also reduced the degree of microglia cell activation across the entire rat
hippocampus and improved the cognitive performance of Tg-AD treated rats compared to agematched untreated Tg-AD rats. IBU also significantly altered the expression of genes associated
with the toll-like receptor signaling pathway and ubiquitin proteasome pathway. Based on my data,
I conclude that IBU has potential as a therapeutic agent for AD.
Goal 2: Explore the Toll-like receptor variations between mice and human brain tissue as it
could affect the efficacy of drugs predicted to treat neuroinflammation in AD (Chapter 3).
Prior investigations determined that the brains of AD patients had increased levels of
microgliosis and pro-inflammatory cytokines. This suggests that Toll-like receptor signaling could
be upregulated in AD brains, likely due to the buildup of extracellular Ab plaques and other
neurotoxic factors that disrupt homeostasis. I performed a literature search to provide a review of
the variation among TLR distribution and levels in human and mouse brain tissue, as it could
impact the predicated efficacy of drugs developed to target these receptors to treat
neuroinflammation in AD.
Goal 3: Determine the therapeutic potential on DZ/DIB co-treatment on AD pathology in a
transgenic rat model of AD (Chapter 4)
I opted to use a combination treatment of DZ and DIB in Tg-AD rats to mitigate the progression
of AD because previous studies examined each drugs’ therapeutic benefits on attenuating
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neurodegeneration and apoptosis in other animal model systems. However, their combined
therapeutic potential was not addressed. I found that DZ / DIB treatment reduced the buildup of
Ab plaques in the hippocampal hilar subregion of the DG, and tau tangle buildup in DG and cornu
ammonis 3 (CA3) hippocampal regions. I did not detect drug treatment effects on microglia or
neuronal loss. However, I found that DZ / DIB treatment decreased eIF2a levels in Tg-AD treated
rats compared to untreated Tg-AD rats. The translation initiator factor eIF2-alpha is a DIB target,
as DIB inhibits its activity, thus reversing stress-induced translational depression.
In collaboration with Charles Wallace, another graduate student in our lab, and using RNA
sequencing analysis, we found that at 4 months of age (pre-pathology stage), gene expression for
the early growth response factor 2 (EGR2) and histone cluster H1 H2AA (HIST1H2AA) was
altered in female Tg-AD rats. Based on these results, I propose that alterations in EGR2 and
HIST1H2AA levels could serve as early AD biomarkers, prior to the development of other
conventional AD hallmarks.
My studies on the effects of the DZ/DIB combination treatment in Tg-AD rats was
complemented by studies carried out by Charles Wallace. Charles established that the DZ/DIB
treatment mitigated spatial memory defects of the Tg-AD rats and improved spatial memory of
WT rats. Based on our results, I conclude that the combination DZ/DIB treatment is an effective
strategy to mitigate AD pathology due to its multi-target approach that affects multiple signaling
pathways.
Conclusions: I found that two novel therapeutic approaches (1) IBU and (2) DZ/DIB combination,
tested on a transgenic rat model of AD, mitigated some aspects of AD pathology. Thus these
multitarget drug approaches should be explored as novel treatments for AD.
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CHAPTER I

INTRODUCTION

1.1. Alzheimer’s disease and neuroinflammation
1.2. The role of Toll-Like receptor signaling in inflammation
1.3. A transgenic rat model of AD that develops full AD pathology in a progressive and agedependent manner

Giovanni Oliveros

Department of Biology,
Hunter College of the City University of New York

New York, New York 10065
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A. ALZHEIMER’S DISEASE AND NEUROINFLAMMATION
1.1 An overview of Alzheimer’s disease
AD currently affects about 5.8 million Americans, the majority of whom are over the age
of 65, with a subpopulation of patients under this age. Experts speculate that by 2050, expenditure
set aside for AD will exceed $2.8 trillion and over 14 million people over the age of 65 will be
affected.1,2 The hallmarks of this disease consist of neuronal loss, amyloid plaques, neurofibrillary
tangles, and neuroinflammation detected in the brain of AD patients.3 In addition, cognitive deficits
associated with AD include loss of memory and progressive impairment of thought and reasoning.
However, the catalysts for setting AD into motion remain unknown. Apart from the
aforementioned changes, evidence has emerged to suggest that there is a genetic predisposition to
AD that leaves vulnerable populations more at risk, with environmental factors and lifestyle
possibly playing a role in disease progression.4
Braak staging is used to describe the progression of AD pathology and Parkinson’s disease
(PD).5 Prior to establishment of the Braak system, it was not possible to determine whether a
patient had succumbed to AD without post-mortem examination. Autopsies of patients suspected
to have suffered from AD have shown that disease progression can be classified under the Braak
staging system, which shows the development of neurofibrillary tau tangles across brain regions.6
Of the six stages (I à VI), staging can be divided into three groups (I – II, III – IV, and V – VI),
with increasing disease severity.7 In the earliest stages (I and II), neurofibrillary tau tangle
involvement is confined mainly to the entorhinal region of the brain, with minimal tau buildup
elsewhere.8 By the next phase (III and IV), tau tangle presence is now seen in limbic region,
including the hippocampus, with more extensive neurofibrillary tangles in the entorhinal region.5
By stages V and VI, tau tangle buildup has now spread to the neocortex.8 9
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Regarding AD diagnostic tools, research has come a long way in terms of developing
biological tests such as positron emission tomography (PET) scans to test for Ab plaques, and
cognitive assessment tests such as the Mini Mental State Examination (MMSE).10 Both tests and
further adaptations have been able to diagnose AD in patients at earlier and earlier stages of disease
progression. This is an advantageous strategy since treatment plans and therapies can be provided
to slow disease progression if the patient is not in an severe disease stage.11

12

Although there is

currently no cure or effective treatment to fully halt AD progression, early diagnosis improves
longevity by slowing the progression of AD through symptom management.

1.2 Neuroinflammation and AD
FDA-approved drugs designed to treat AD by way of targeting amyloidogenesis or
tauopathies, do not halt disease progression, having a reported 99.6% failure rate.13 This failure
can be attributed to the complexity of AD, and its pathological changes, such as accumulation of
Ab plaques, tau tangles, and neuroinflammation.3 Neuroinflammation occurs when there is cellular
damage in the brain, leading to recruitment of glial cells such as microglia and astrocytes, to clear
up the damage and restore neuronal function.14 However, chronic neuroinflammation resulting
from persistent activation of pro-inflammatory responses in combination with delays in antiinflammatory responses, causes buildup of cellular debris and neuronal damage. Selecting
neuroinflammation as a therapeutic strategy to combat AD may prove beneficial, considering the
promises it has shown with treating other neurodegenerative disorders, such as amyotrophic lateral
sclerosis (ALS) and multiple sclerosis (MS).15 16 Therapeutics aimed at these two disorders showed
promise by amplifying the neuroprotective properties of glial cells, a strategy that could be
mimicked for targeting AD pathology from the neuroinflammatory perspective.15 16 17 18 19 20 21 22 23
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B. THE ROLE OF TOLL LIKE RECEPTOR SIGNALING IN INFLAMMATION
1. Activation of the Toll-Like Receptor signaling pathway
Toll-like receptors (TLRs) are a family of proteins on the surface of immune cells that
recognize molecular structures that are largely shared by products released by pathogens, and then
initiate an appropriate immune response such as inflammation.24 TLR signaling pathways are
stimulated

by

pathogen-associated

molecular

pattern

molecules

(PAMPs),

such

as

lipopolysaccharides (LPS) produced by Gram-negative bacteria, or via damage-associated
molecular pattern molecules (DAMPs), like Ab.25 Upon TLR activation, the myeloid differentiator
protein 88 (MyD88) is recruited to the TLR on the cytoplasmic face. Then interleukin-1 receptor
associated kinase (IRAK) 4 is recruited to MyD88 and subsequent binding will occur between the
two proteins along their N-terminal death domains (DD).26 Upon IRAK4 binding,
autophosphorylation occurs, allowing for the binding of IRAK1 to IRAK4, and formation of the
whole myddosome complex.27 IRAK4 then induces the phosphorylation of IRAK1, with its
subsequent release from the myddosome. Phosphorylated-IRAK1 (pIRAK1) then binds TRAF6,
leading to subsequent activation of transforming-growth factor (TGFb) associated kinase 1
(TAK1) via phosphorylation. Following subsequent interaction with TAK-binding protein 2
(TAB2), p-IRAK1, TRAF6, and TAK1 will activate the inhibitor of kappa-B kinase (IKK) by way
of ubiquitination and phosphorylation.28

29

This will lead to phosphorylation of the Inhibitor of

kappa B (IkB) and its dissociation from NFkB. Liberated NFkB will translocate to the nucleus and
promotes the transcription of pro-inflammatory cytokines.30 (Figure 1.1)
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PAMPs DAMPs
extracellular

TLR
MyD88
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IRAK4
IRAK1
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IkB/NFkB
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NFkB
nucleus

Cytokines

Figure 1.1: Toll-Like Receptor Signaling Pathway. Upon activation of TLRs, MyD88 is
recruited to the cytoplasmic side and is tethered to TLR. MyD88 binding then recruits IRAK4,
which subsequently recruits IRAKs 1 and 2 to form the myddosome complex. IRAK1 activation
and phosphorylation by IRAK4 induces IRAK1 dissociation from the myddosome. IRAK1 will
then bind and phosphorylate TRAF6, a ubiquitin ligase. TRAF6 activation will continue the signal
cascade, triggering dissociation of IkB from NFkB, which translocates to the nucleus and induces
cytokine transcription.
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2. The role of IRAK1 as a master regulator of the Toll Like Receptor Pathway
IRAK1, a member of the toll-like receptor (TLR) signaling pathway, is a 78kDa protein
comprised of ~710 amino acids. Its structure consists of an N-terminal Death Domain, Pro-SerThr Domain, a kinase domain, followed by a C1 TRAF6-binding domain (Figure 1.2).31 Compared
to other IRAKs [such as IRAK2, IRAK3 (also referred to as IRAK-M), and IRAK4], IRAK1 shares
the distinction of containing the first three domains. Only IRAKs 1 and 4, however, contain a
functional kinase domain, dubbing them true kinases, while IRAKs 2 and 3 function as pseudokinases.27 Within the kinase domain, an adenosine triphosphate (ATP) binding site was identified,
which is often selected as the site of experimental manipulation. A non-IRAK protein that shares
the distinction of possessing an N-terminal Death Domain is MyD88, necessary for protein
binding.30 Compartmentalization of these domains is essential for the mechanisms of action that
IRAK1 uses when stimulated within the TLR signaling pathway.
Initially, IRAK1 is found complexed to an adaptor protein, Tollip.32 Stability of this
complex is necessary to prevent activation of IRAK1 in the absence of a pro-inflammatory
stimulus. When the TLR pathway is activated, recruitment of IRAK1 to the myddosome (MyD88
+ IRAK4) occurs, with subsequent IRAK1 trans-autophosphorylation weakening its interaction
with Tollip.33 Mutation studies showed that overexpression of Tollip suppresses activation of the
TLR pathway, leading to reduced NF-kB release and JNK signaling.34
As an E3 ubiquitin ligase, TRAF6 assists IRAK1 in carrying out the TLR cascade by
making

a

complex

with

p-IRAK1,

allowing

p-IRAK1

to

phosphorylate

TAK1.31

Polyubiquitination, formed by lysine-48 (K48) chains, are added onto IRAK1 following
phosphorylation of TAK1. This ensures that p-IRAK1 does not remain constitutively active in the
cell. Once polyubiqutinated, p-IRAK1 undergoes proteasomal degradation, with TLR signaling
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maintained by the pseudo kinase, IRAK2 binding to IRAK4 on the myddosome following
degradation of IRAK1.31 IRAK3 (IRAK-M) however, has been shown to be an inhibitor of the
TLR pathway, likely functioning by stabilizing IRAK1 and preventing its binding to IRAK4 on
the myddosome. Polyubiquitination of TRAF6 however occurs via lysine-63 (K63) linkages,
leading to further activation of downstream cascades in TLR signaling, such as the
phosphorylation of TAK1 and activation of IkB kinase (IKK) (Figure 1.3).35 36 37
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• N-terminal Death Domain
• Proline-Serine-Threonine Rich Domain (Pro-ST domain)
• Kinase Domain
• C1 and C2 Domains (TRAF6 Binding Domain)
∆ 514-543 – IRAK1b
∆ 460-538 – IRAK1c
Death Domain
103

Pro-ST Domain

Kinase Domain
198

T66 – Important for Dimerization

C2 Domain

C1 Domain

Activation Loop
(364-388 aa)

522

618

712

K238 – Important for Kinase Activity

T209 – Phosphorylated by IRAK4

D340

T387
Gottipati, Rao, Fun—Leung, Cellular Signaling, 2008

Figure 1.2: IRAK1 Domain Architecture: IRAK1 is composed of an N-terminal Death Domain
(residues 1 – 102), Pro-ST Domain (residues 103-198), Kinase Domain (residues 199-521), and
C-terminal domain (residues 522-712). Within the Death Domain is the threonine-66 residue,
responsible for dimerization. In the Kinase domain, there are two threonine residues (209 and 387)
which are phosphorylated by IRAK4. There are also two key residues (lysine at position 238 and
glutamate at position 340) that are essential for kinase activity. The C-terminal domain is divided
into two subdomains (C1 ranges from residue 522 – 617 and C2 ranges from 618 – 712). The
TRAF6 binding domain is located within the C-terminal region.
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Figure 1.3. Proposed mechanism for IBU inhibition of TLR signaling. IBU has been predicted
to target IRAK1 using our bioinformatics algorithm that matches previously FDA approved drugs
to potential targets by exploiting off-target effects. An inhibition of IRAK1 would prevent further
TLR signaling and lead to reduced cytokine secretion by NFkB.
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3. Ibudilast as a Toll-Like Receptor 4 antagonist and IRAK1 inhibitor
Our lab currently participates in an NIH grant to repurpose FDA-approved drugs to treat
AD. The study focuses on using computational algorithms to find compounds that have the
potential to be beneficial in treating AD pathology. Ibudilast (IBU) is one of those drugs. IBU is a
non-selective phosphodiesterase (PDE) inhibitor predicted to be an IRAK1 antagonist by Dr. Lei
Xie (Dept. Computer Science, Hunter College), our collaborator and PI on the NIH grant.
IBU is a Japanese medication previously recommended for the treatment of post-stroke
complications and asthma.38 The primary mode of action of IBU is by way of neuroprotection and
anti-inflammatory effects, with some studies suggesting that it targets the macrophage migratory
inhibitory factor (MIF1).39 MIF is found in the cytoplasm but exits to the extracellular space when
stimulated by endotoxins, cytokines, and glucocorticoids. At this point, MIF regulates macrophage
function by suppression of anti-inflammatory effects.40 Its mechanism of action involves activation
of the CD74 receptor when complexed with CD44; alternate targets include CXCR2 and CXCR4.40
IBU functions as a non-competitive inhibitor to MIF, suppressing leukotriene B4, proinflammatory cytokine production, and prevents production of nitric oxide.40
In a clinical trial for opioid withdrawal, IBU was shown to be a TLR4 antagonist and to
reduce glial cell activation.41 Moreover, IBU has shown promise in clinical trials against multiple
sclerosis (MS) and amyotrophic lateral sclerosis (ALS).42
IBU treatment of MS stems from its prior success as a neuroprotective agent that generates
an anti-inflammatory response, with the advantage of being blood brain barrier (BBB) permeable.
As a phosphodiesterase inhibitor, IBU can maintain cyclic AMP levels and inhibit T-cell immune
function.43 Furthermore, IBU helps promote IL-10 production, while simultaneously inhibiting
production of TNFa and NO.44 A phase two clinical study for progressive MS focused on
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measuring development of new lesions using MRI and the rate of diminishing brain parenchymal
fraction, indicating the accumulation of cerebral spinal fluid where brain tissue would normally
be.45 After daily treatment with 100 mg of IBU for 96 weeks, most patients exhibited less reduction
of brain parenchymal fraction from -0.0019/year for placebo treated patients to -0.0010/year for
IBU-treated patients, indicating a roughly 2.5mL reduction of brain volume loss. These results
were significant, if intervention occurred in the early stages of the disease.46
Clinical trials for ALS showed that IBU in combination with Rilutek halted disease
progression in ALS (clinical trial NCT02238626), with results being more meaningful in patients
with shorter histories of ALS (less than 600 days since disease onset).

1.3 A TRANSGENIC RAT MODEL OF AD THAT DEVELOPS FULL AD PATHOLOGY
IN A PROGRESSIVE AND AGE-DEPENDENT MANNER
1.3.1

Previous AD rodent models
Considering the complexity of AD, several factors must be considered aside from the

hallmarks of the disorder. AD does not occur by itself, meaning that patients will often suffer from
a secondary disease concurrently. In addition, patients with AD are aging, which leads to a myriad
of health problems and increased risk for certain disorders, such as cancer, impaired organ
function, increased likelihood for metabolic dysregulation, and muscle atrophy. These factors
should be considered when selecting a model system to investigate AD therapeutic interventions.
The 5X familial mouse model of AD (5X FAD) expresses human APP with three mutations
and presenilin1 (PSEN1) with two mutations.47 This model is chosen by some investigators due to
the accelerated timeline in Ab deposition detected at a mere two months of age.48 This model
system however does not display tauopathies, nor does it consider aging as a risk factor. These
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weaknesses could diminish the significance of therapeutics when attempting to crossover to more
complex model systems and human clinical trials.
Although a step in the right direction towards developing a more sophisticated AD rodent
model, the 3X Tg mouse model suffers from some of the same problems of the 5X FAD model,
namely the possible absence of neuronal loss we see in human AD progression. The 3X Tg mouse
model does supersede the 5X FAD mouse model in that it does show extracellular Ab by six
months, gliosis, and neurofibrillary tau tangles despite its shortcomings.49

1.3.2

The TgF-344AD rat model and its advantages over previous AD rodent models
The transgenic TG-AD Fisher 344 (Tg-AD) rat model has been considered a more realistic

model for AD investigations.50 Tg-AD rats present the full array of AD pathology in a progressive
manner including gliosis, cerebral amyloidosis that precedes tauopathy, apoptotic loss of neurons
in the cerebral cortex and hippocampus, and cognitive impairment, all in an age-dependent manner
(Figure 1.4).50
Tg-AD rats express mutant human “Swedish” amyloid precursor protein (APPsw) and D
exon 9 presenelin-1 (PS1DE9) at 2.6- and 6.2-fold higher levels than the endogenous rat proteins.
Expression of the two human mutant transgenes is driven by the prion promoter. There seems to
be no pathology difference between sexes in this rat model of AD.50 Tg-AD rats develop agedependent amyloid plaques in the hippocampus and cortex, accompanied by astrogliosis,
microgliosis and cognitive impairment (Morris water maze), at 6 months of age (Figure 1.3). By
15-16 months of age, neurofibrillary tangles and neuronal loss are fully established in Tg-AD
rats.50 Considering that previously mentioned AD models either fail to display all aspects of AD
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pathology or fail to consider aging as a risk factor, we selected the Tg-AD rat model for our invivo studies because it more accurately depicts disease progression like in human AD.
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Figure 1.4: Timeline for developing AD pathology in the Transgenic Fisher 344 – Alzheimer’s
Disease Rat model. Age-dependent accumulation of soluble Ab1-40 and increases in insoluble Tau
begin by six months. At this age rats also begin to develop microgliosis and astrogliosis. By 16
months of age, cognitive deficits are observed, along with Ab deposition and formation of
neurofibrillary tangles. Neuronal loss and apoptosis is also present, with evidence of accumulation
of intraneuronal Ab1-42.
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2.1 ABSTRACT
Alzheimer’s disease is a multifactorial disease that exhibits cognitive deficits, neuronal
loss, amyloid plaques, neurofibrillary tangles and neuroinflammation in the brain. Hence, a multitarget drug would improve treatment efficacy. We applied a new multi-scale predictive modeling
framework that integrates machine learning with biophysics and systems pharmacology to screen
drugs for Alzheimer’s disease using patient’s tissue samples. Our predictive modeling framework
identified ibudilast as a drug with repurposing potential to treat Alzheimer’s disease. Ibudilast is a
multi-target drug, as it is a phosphodiesterase inhibitor and toll-like receptor 4 (TLR4) antagonist.
In addition, we predict that ibudilast inhibits off-target kinases (e.g., IRAK1 and GSG2). In Japan
and other Asian countries, ibudilast is approved for treating asthma and stroke due to its antiinflammatory potential.
Based on these previous studies and on our predictions, we tested for the first time the
efficacy of ibudilast in Fisher transgenic 344-AD rats. This transgenic rat model is unique as it
exhibits hippocampal-dependent spatial learning and memory deficits, and Alzheimer’s disease
pathology including hippocampal amyloid plaques, tau paired-helical filaments, neuronal loss and
microgliosis, in a progressive age-dependent manner that mimics the pathology observed in
Alzheimer’s disease patients. Following long-term treatment with ibudilast, transgenic rats were
evaluated at 11 months of age for spatial memory performance and Alzheimer’s disease pathology.
We demonstrate that ibudilast-treatment of transgenic rats mitigated hippocampal-dependent
spatial memory deficits, as well as hippocampal (hilar subregion) amyloid plaque and tau pairedhelical filament load, and microgliosis compared to untreated transgenic rat. Neuronal density
analyzed across all hippocampal regions was similar in ibudilast-treated transgenic compared to
untreated transgenic rats. Interestingly, RNA sequencing analysis of hippocampal tissue showed
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that ibudilast-treatment affects gene expression levels of the TLR and ubiquitin/proteasome
pathways differentially in male and female transgenic rats. Based on the TLR4 signaling pathway,
our RNA sequencing data suggest that ibudilast-treatment inhibits IRAK1 activity by increasing
expression of its negative regulator IRAK3, and/or by altering TRAF6 and other TLR-related
ubiquitin ligase and conjugase levels.
Our results support that ibudilast can serve as a repurposed drug that targets multiple pathways
including TLR signaling and the ubiquitin/proteasome pathway to reduce cognitive deficits and
pathology relevant to Alzheimer’s disease.
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2.2 INTRODUCTION
Alzheimer’s disease currently affects about 5.8 million Americans, the majority of which
are over the age of 65, with a subpopulation of patients under this age cutoff. Experts speculate
that by 2050, expenditure set aside for Alzheimer’s disease will exceed $2.8 trillion and over 14
million people over the age of 65 will be affected.1 The hallmarks of this disease consist of
neuronal loss, amyloid plaques, neurofibrillary tangles, and neuroinflammation detected in the
brain of Alzheimer’s disease patients.3 In addition, cognitive deficits associated with Alzheimer’s
disease include loss of memory and progressive impairment of thought and reasoning. However,
the catalysts for setting Alzheimer’s disease into motion are still being investigated. Aside from
the aforementioned changes, evidence has emerged to suggest that there is a genetic predisposition
to Alzheimer’s disease that leaves vulnerable populations more at risk, with environmental factors
and lifestyle possibly playing a role in disease progression.4
FDA-approved drugs designed to treat Alzheimer’s disease through targeting plaques or
tangles, do not halt disease progression, having a reported 99.6% failure rate.13 This failure can be
attributed to the complexity of Alzheimer’s disease, not just the plaques or tangles.3 One such
factor contributing to the pathology of Alzheimer’s disease is neuroinflammation. This occurs
when there is cellular damage in the brain, leading to recruitment of microglia and astrocytes to
clear the damage and restore neuronal function.14 However, chronic neuroinflammation resulting
from persistent activation of pro-inflammatory responses in combination with delays in antiinflammatory responses, causes buildup of cellular debris and neuronal damage. Selecting
neuroinflammation as a therapeutic strategy to combat Alzheimer’s disease may prove beneficial,
considering the promises it has shown with treating other neurodegenerative disorders, such as
amyotrophic lateral sclerosis and multiple sclerosis.15 16 Therapeutics aimed at these two disorders
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showed promise by amplifying the neuroprotective properties of glial cells, a strategy that could
be mimicked by targeting Alzheimer’s disease pathology from the neuroinflammatory perspective.
To identify existing drugs that can modulate neuroinflammation in Alzheimer’s disease,
we applied a predictive modeling framework that integrates machine learning with biophysics and
systems pharmacology to repurpose approved drugs for Alzheimer’s disease treatment. Our model
predicted that ibudilast (IBU), a nonselective phosphodiesterase inhibitor and a TLR4 antagonist,
inhibits IRAK1 as an off-target, modulates multiple Alzheimer’s disease-associated pathways, and
reverses Alzheimer’s disease patient’s molecular phenotypes.21 51 52 53,54 The primary mode of
action of IBU is by way of neuroprotection and anti-inflammatory effects. In a clinical trial for
opioid withdrawal, IBU was shown to be a TLR4 antagonist and to reduce glial cell activation.41
Moreover, IBU has shown promise in clinical trials against multiple sclerosis and amyotrophic
lateral sclerosis.42
Results from a phase-two clinical trial for progressive multiple sclerosis reported that after
96 weeks of treatment, IBU-treated patients exhibited less brain atrophy than placebo-treated
patients.45 IBU effects were significant, provided that intervention occurred in the early stages of
the disease.46 Based on this study, we evaluated the effects of long-term (six-months) treatment of
IBU in an age-dependent transgenic rat model of Alzheimer’s disease (Tg-AD) for improvement
in spatial memory and mitigation of hippocampal Alzheimer’s disease pathology.

2.3 MATERIALS AND METHODS
2.3.1

TgF-344 AD transgenic rat model of Alzheimer’s disease and ibudilast treatment

19

Fisher transgenic 344-AD (Tg-AD) rats expressing human Swedish amyloid precursor
protein (APPsw) and D exon 9 presenelin-1 (PS1DE9) were purchased from Rat Resource and
Research Center (RRRC, Columbia, MO).55 The Tg-AD rats (16 males; 13 females) and wild type
(WT) (15 males; 15 females) were housed in pairs upon arrival and maintained on a 12h light/dark
cycle with food and water available ad libitum. The Institutional Animal Care and Use Committee
at Hunter College approved all animal procedures.
At five months Tg-AD and WT rats began IBU (cat # HY-B0763, MCE, Monmouth
Junction, NJ) treatment, 10 mg/kg body weight administered in rodent chow (Research Diets Inc.
NJ, Supplemental Figures 1 and 2). Untreated Tg-AD and WT controls received non-drug chow.
Following six months of IBU treatment rats (11 months of age) were tested for cognitive behavior
prior to sacrificing. Brains were examined by immunohistochemistry (IHC) and RNA sequencing
(RNAseq) analyses.
2.3.2

Cognitive behavior assessment
We used the Active Place Avoidance Task (aPAT) to assess hippocampal spatial learning

and memory performance56. The arena is comprised of a rotating platform that operates at one
revolution per minute (rpm), with visual cues at the four walls of the room. The arena is divided
into four quadrants, one of which will be assigned as a shock zone. If a rat enters the shock zone
and remains there for at least 1.5 seconds, it will receive a 0.2 amp shock. A shock is given every
1.5 seconds until the rat leaves the shock zone. An overhead camera is perched atop of the arena
to track the location of the rat as it performs the task. Rats were given a 10 minute habituation trial
(no shock), followed by six 10 minutes training trails, with a 10 minute inter trial interval in the
home cage. 24 hours after the last training trial, rats received one 5-minute test trial with the shock
zone turned off.
20

2.3.3

Immunoflourescence
At 11 months of age, the rats were anesthetized intraperitoneal with ketamine (100 mg/kg)

and xylazine (10 mg/kg), and transcardially perfused with cold RNAse-free 1X PBS. Left
hippocampi were removed and snap frozen for RNAseq analysis. Right hemispheres were
submersion fixed with 4% paraformaldehyde for 48 hours at 4oC and cryoprotected (30%
sucrose/PBS) then flash frozen in 2-methybutane, and stored at -80oC until cryostat sectioned.
Coronal sections through the hippocampus (30 µm) were collected serially and stored at -20°C in
cryoprotectant (30% glycerol and ethylene glycol in 1X PBS). Immunohistochemical (IHC)
analyses was restricted to hippocampal sections -3.36 mm to -4.36 mm relative to bregma, and
followed a protocol for mounted sections described previously.57 58
2.3.3.1 Ab plaques and microglia
Primary antibodies were diluted at 1:1000 for Ab (4G8 antibody, epitope a.a. 17-24,
Biolegend – mouse – cat# 800708) and 1:500 for microglia (Iba1, Wako – rabbit – cat# 01919741). Secondary antibodies included Alexa Fluor goat anti-mouse 568 (cat# A-11031) and
Alexa Fluor goat anti-rabbit 488 (cat# A-11008), both at a 1:250 concentration and from Life
Technologies, Thermo Fisher Sci. Following immunostaining, VectaShield® mounting media with
DAPI (cat# H-1200-10) was used and slides were stored at 4°C in the dark until imaged. We used
a Zeiss Axio Imager microscope equipped with AxioVision software to capture whole
hippocampal images as ZVI files that were loaded onto Image J (NIH).
Ramified, reactive, and amoeboid microglia phenotypes were analyzed for circularity
based on the ImageJ form factor (FF = 4π x area/perimeter2): ramified (FF < 0.50), reactive (FF,
0.50 – 0.70), and amoeboid (FF > 0.70), where microglia with an area between 50 – 1000 µm2
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were included.59,60 Microglia signal intensity (O.D.) was quantified based on our previous
reports.58,61
2.3.3.2 Neurons and tau PHF
A similar IHC protocol as for Ab and Iba1 was used, with the following changes: (a)
washes with 0.3 % TritonX (Thermo Fisher, cat# PI85112) in 1X TBS (TBS-T); (b) blocking with
dry milk (5 % by weight) in 0.3 % TBS-T; (c) primary antibodies prepared in the same blocking
buffer.62 Primary antibodies diluted to 1:250: PHF1 antibody for tau PHF (courtesy of the late Dr.
Peter Davies) and NeuN (Millipore – chicken – cat# ABN91) for neuronal density. The secondary
antibody cocktail was prepared in 20 % Superblock/TBS in 0.03 % TBS-T. Secondary antibodies
used: Alexa Fluor IgG1 goat anti-mouse 568 (1:80 dilution, cat# A-21124) and Alexa Fluor goat
anti‐chicken 488 (1:250 dilution, cat# 11039) both from Life Technologies, Thermo Fisher.
Images of hippocampal subfields (CA1, CA3, DG, and SB) were analyzed with custom
batch-processing macroscripts created for each channel/marker. Pixel-intensities were calculated
from the images at 16-bit intensity bins. Positive signal within each cropped image was extracted
using a formula as previously described previously.63 Positive signals were then measured, masks
created, and merged when co-localization analyses were required.
2.3.3.3. RNAseq analysis
Hippocampi of five IBU-treated and five untreated transgenic rats of each sex were
analyzed for gene expression by RNAseq at the UCLA Technology Center for Genomics &
Bioinformatics outsourcing service. Gene expression data were normalized as reads per million
(RPM) using the TMM method. Differentially expressed genes from IBU-treated transgenic rats
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were determined using the edgeR program.64 RPMs were analyzed for fold-change, p-values, and
FDR for each gene (Supplementary Table 6).
2.3.3.4 Statistical analysis
For our behavioral analyses we required a minimum of 14 animals per condition in order
to reach statistical significance at the 5 % level. We processed all brains for IHC and all were
analyzed for the various markers, except for four brains which were damaged during processing.
For every IHC data set we ran a PRISM ROUT outlier test set at Q = 1%. There were no outliers
detected for Ab, PHF1, or NeuN data sets. There were three outliers detected for the Iba1 data set.
For IHC and behavioral assessments, two-way ANOVAs were used to analyze differences between
genotype and treatment. Repeated measures ANOVA were used to assess differences across time
for behavioral analyses. For memory retention testing and microglial analysis, ordinary two-way
ANOVA were used. Post-hoc analyses used controlled Sidak’s-corrected t test comparisons. Onetail independent t-tests were used for analysis of neuronal density, Ab plaque, and tau paired
helical filament accumulation. For image quantification, normalization of pixel intensity values
across images was done utilizing the rolling ball algorithm65. The macroscripts necessary for image
processing

and

quantification

were

added

to

GitHub

https://github.com/GiovanniOliveros33/Ibudilast-Manuscript). The alpha level was set at P < 0.05
with a 95% confidence interval for each effect. GraphPad’s Prism version 8 (La Jolla, California)
was used.
To measure differences in gene expression between ibudilast treated and untreated male
and female transgenic rats, multiple unpaired t-tests with Welch’s correction were used, for each
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comparison. For these analyses, the expression level of each gene for male or female treated
transgenic rats was the percent expression of their untreated counterparts normalized to 100%.
2.3.4

Kinase binding assay
To validate our computational predictions, we employed a competition biding assay to

detect the binding of IBU to 425 human kinases. The proprietary KINOMEScanTM was performed
by Eurofins/DiscoverX (Fremont, CA). The tests were performed at 10 µM and 100 µM
concentrations of levosimendan, respectively. Assay results were reported as % control, calculated
as follows:
(𝑡𝑒𝑠𝑡 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙 − 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑠𝑖𝑔𝑛𝑎𝑙)
𝑋 100 (1)
(𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑠𝑖𝑔𝑛𝑎𝑙 − 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑠𝑖𝑔𝑛𝑎𝑙)
A lower % control score indicates a stronger interaction. The KINOMEScanTM experiment and
data analysis were performed by Eurofins/DiscoverX (Fremont, CA).
2.3.5

Multi-scale predictive modeling of drug action
Derivation of Alzheimer’s disease Signature: We selected six out of ten human microglial

RNAseq samples (four Alzheimer’s disease, two controls) obtained from ROSMAP projects
through AMP-AD Knowledge Portal (Supplementary Table 5).66 We selected the samples which
were identified with unambiguous AD or as normal/unaffected controls. The four samples that
were excluded from the analyses were samples diagnosed as reflecting a different disorder (labeled
“Other”) not associated with AD. We used Salmon to quantify the transcripts and DEseq2 to
perform the differential expression analysis.67 68 The top differentially expressed genes (adjusted
P value < 0.05) were used as Alzheimer’s disease signatures for further analysis.

24

Phenotypic compound screening: The up and downregulated genes in the Alzheimer’s
disease signature, who also served as LINCS L1000 landmark genes, were used to screen druginduced expression profiles in the L1000 dataset. The drug-induced expression profiles were
processed by Bayesian signature detection pipeline and compared to the Alzheimer’s disease
signature by Gene Set Enrichment Analysis (GSEA).69 70 Drugs with the lowest scores are selected
as candidates. Prediction of genome-wide drug-target interactions: We applied 3D-REMAP to
predict drug off-target binding of IBU as described previously.71
Text mining for drug-gene-disease associations: The details of methods were as previously
described.71
Prediction of BBB permeant: The BBB permeant of chemical compounds was predicted
using SwissADME.72

2.4
2.4.1

. RESULTS
Ibudilast is predicted to be a drug candidate for Alzheimer’s disease treatment
Our structure systems pharmacology pipeline for the first-time integrated structure-based

genome-scale off-target predictions and chemical-induced gene expression predictions for
screening approved or investigational drugs to target AD. The scheme of the pipeline is shown in
supplemental figure 3. We ranked drugs by their ability to reverse the gene expression profile of
Alzheimer’s disease patients.73 We first obtained the differential gene expression profile of
microglia from a group of Alzheimer’s disease patients vs healthy controls in the AMP-AD data
portal, and considered it as the molecular phenotypic signature of Alzheimer’s disease
(Supplementary Table 1).74 Then we compared the drug-induced gene expression profile of
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approximately 20,000 drugs (dosage < 1 μM) with the Alzheimer’s disease signature such that the
downregulated and upregulated genes in Alzheimer’s disease will be upregulated and
downregulated by the drug, respectively. Of the top 100 ranked drugs (Supplementary Table 2),
three of them are anti-inflammatory drugs, as shown in Table 1. Because sulfasalazine and
sasapyrine may not be able to permeate the blood-brain-barrier (BBB), we focused our studies on
IBU.
Using a structure-augmented machine learning method for predicting genome-scale drugtarget interactions, we predicted that protein kinases were the off-target of PDE3A inhibitors.75
The KinomeScanTM assay confirmed our predictions. IRAK1 and HASPIN (GSG2) are effectively
inhibited by IBU under the concentration of 10 μM with a percentage control of 6.8 and 9.4,
respectively (Supplementary Table 3). IRAK1 is involved in the TLR and interleukin-1 signaling
pathways and plays a key role in regulating inflammation. Genome-Wide Association Studies
(GWAS) discovered that GSG2 is located in the locus associated with Alzheimer’s disease.76
Additionally, KIF proteins, the downstream target of GSG2, are related with AD.77 Thus, either or
both genes could be involved in disease risk. Under a high concentration of 100 μM, IBU inhibits
multiple kinases that are associated with Alzheimer’s disease and inflammation, such as PIK3C3,
CDK4, JNK1, JNK3, HIPK2, HIPK3, TAOK1, TAOK3 (Supplementary Table 4).
The hypothesis that IBU modulates multiple Alzheimer’s disease-associated pathways was
further supported by text mining.71 We found that IBU was associated with multiple Alzheimer’s
disease pathological processes including TLR/MYD88/NFkB pathways, TNF pathway,
lipopolysaccharide synthesis pathway, and herpes simplex virus infection with the false discovery
rate (FDR) less than 1.0e-3.
2.4.2

Ibudilast improves spatial learning and memory
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The hippocampal-dependent active place avoidance task was used to assess short-term
working memory performance on 11 month old Tg-AD and wild type (WT) rats (Fig. 2.1A). Male
and female performances were combined to four groups: wild-type untreated (WTNT), wild type
treated with IBU (WTTR), transgenic untreated (TGNT), and transgenic treated with IBU (TGTR).
A three-way ANOVA analysis of aPAT performance across six training trials, two drug treatments
(ibudilast treatment and no treatment), and two genotypes (wild-type and transgenic) with
Bonferroni’s post-hoc analysis measuring latency to first entrance into the shock zone revealed an
overall significant effect of training (F(4.528, 244.5) = 13.28; p < 0.01) and an overall significant effect
of genotype (F(1,54) = 5.96; p = 0.02). No post-hoc differences were observed for any analyses
performed under this repeated measures ANOVA, nor were ibudilast treatment effects observed
under this three-way analysis. To determine whether short-term working memory deficits were
more pronounced during the early acquisition phase (trials 1-3) versus asymptotic performance
phase (trials 4-6), we analyzed these phases separately. Our three-way ANOVA analysis of early
acquisition in latency to first entrance showed significant training effects (F(1.794, 96.88) = 9.811; p <
0.01), genotype effects (F(1, 54) = 14.28; p < 0.01), and an effect of ibudilast treatment with respect
to genotype (F(1, 54) = 7.582; p < 0.01). No significant post-hoc differences were observed, nor
were there any significant effects observed during the asymptotic performance phase of training.
Independent two-way repeated measures ANOVA with Sidak’s post-hoc tests were
performed across training trials to isolate the effects of either genotype (analyses of WTNT vs.
TGNT and WTTR vs. TGTR) or ibudilast treatment (WTNT vs. WTTR and TGNT vs. TGTR)
across training trials, again assessing latency to first entrance to the shock zone while considering
the early acquisition and asymptotic performance phases of training. Our results show that at 11
months of age WTNT rats performed significantly better during acquisition (trials 1-3) compared
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to TGNT (F(1,25) = 28.53, P < 0.01) with post-hoc differences at trials 2 and 3 (t = 2.839, P < 0.01
and t = 3.494, P = 0.01 respectively; Fig. 2.1B). Following 6 months of IBU-chow or control chow,
TGTR rats show significant improvement during acquisition compared to TGNT controls (F(1,26)
= 4.603, P < 0.01) with post-hoc differences at trial 3 (t = 2.639, P = 0.05; Fig. 2.1D). This
enhanced performance was not observed between WTNT and WTTR conditions (F(1,28) = 2.525,
P = 0.1233), suggesting beneficial effects of IBU-treatment under pathological conditions (Fig.
1E). TGTR rats performed equivalently to WTTR controls (F(1,29) = 0.4481, P = 0.5085; Fig. 2.1C).
There were no significant effects observed during asymptotic performance (trials 4 – 6) across
genotypes or treatments. We also saw that TGTR rats performed significantly worse than WTNT
rats in the early acquisition phase (F(1,27) = 6.621, P = 0.02), but not in asymptotic performance
phase (F(1,27) = 0.063, P = 0.80). (Supplemental Figure 4A), while TGNT rats performed
significantly worse than WTTR rats (F(1,27) = 4.052, P = 0.03) in early acquisition (Supplemental
Figure 4B). Fig. 2.1F shows the tracking for individual rats during trial 3 across the four treatment
conditions. 24h after the last training trials we tested rats for avoidance of the shock zone in the
absence of shock. The results show that IBU treated rats performed better than controls for max
latency to avoid the shock zone, regardless of genotype (F(1,55) = 4.033, P = 0.0495) (Fig. 2.1G).
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Figure 2.1: Ibudilast treatment mitigates spatial learning and memory performance
deficits. (A) Experimental timeline. (B-E) Latency to first entrance during training. (B) Early
acquisition (EA) shows significant differences between WTNT vs TGNT rats. (D) TGTR perform
significantly better than TGNT during EA. No differences in EA between (E) WTNT vs WTTR
and (C) WTTR and TGTR. (B-E) No differences were observed in asymptotic performance
(Trials 4-6) across all comparisons. (F) Track tracing of individual rat performance for trial 3
across treatment conditions. (G) Test data show overall significant improvement in maximum time
to avoid during test following ibudilast treated vs untreated. Repeated measures two-way ANOVA
with Sidak’s post-hoc tests were used in 1B through 1E. Ordinary two-way ANOVA with Sidak’s
post-hoc analysis was used in 1G. n = 14 WTNT, n = 13 TGNT, n = 15 TGTR, n = 16 WTTR. *
P < 0.05, ** P < 0.01. EA - Early Acquisition; AP – Asymptotic Performance; WTNT – Wildtype Not Treated; TGNT – Transgenic AD – Not Treated; WTTR – Wild-type ibudilast treated;
TGTR – transgenic AD – Ibudilast treated; *d – ibudilast drug treatment effect.
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2.4.3

Ibudilast significantly reduces Ab plaque burden in the dentate gyrus
We evaluated Ab plaque burden in the hippocampus and within its discrete subregions

(Fig. 2.2A-B), between IBU-treated and untreated Tg-AD rats. We found that Ab plaque burden
following IBU-treatment was not significantly different from untreated Tg-AD rats in the
hippocampus collapsed across subregions (Fig. 2.2C; t = 0.08131, P = 0.9359). Analyses of
subregions separately shows significant reduction in Ab plaque load in the dentate gyrus (Fig.
2.2F; t = 3.449, P = 0.021). However, no significant effects in CA1 (Fig. 2.2D; t = 0.5707, P =
0.5735), CA3 (Fig. 2.2E; t = 0.3351, P = 0.7405) and subiculum (SB) (Fig. 2.2G; t = 0.3020, P =
0.7652) were identified. Alongside quantification of Ab plaque load, we also quantified the percent
positive signal for DAPI for all rat hippocampi included in the analysis for the entire hippocampus
and its regions CA1, CA3, DG, and subiculum. Hippocampi and corresponding regions were
compared between transgenic untreated and transgenic-IBU treated rats using two-tailed unpaired
t-tests with Welch’s corrections. We found no significant differences between percent positive
DAPI signal throughout the hippocampus (p = 0.85), or the subregions CA1 (p = 0.26), CA3 (p =
0.42), DG (p = 0.86), and the subiculum (p = 0.81) between transgenic untreated and ibudilasttreated transgenic rats (Supplemental Table 7).
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Figure

2.2: Ibudilast treatment

reduces

Ab plaque

load

regionally

across

hippocampal subregions. Immunohistochemistry for Ab plaque load and DAPI for (A) untreated
and (B) ibudilast-treated Tg-AD rats. Scale bar = 1000µm for panels (A) and (B). Plaque load was
not

reduced

across

hippocampal

subregions (C) collapsed,

or

in (D) CA1, (E) CA3

and (G) subiculum. (F) Ibudilast-treatment significantly reduced plaque load in DG. Unpaired
one-tail t-tests with Welch’s corrections were used in 1C through 1G. n = 12 TGNT, n = 14 TGTR.
* P < 0.05. CA1 – Cornu Ammonis; DG – Dentate Gyrus; SB – subiculum; TGNT – Transgenic
AD – Not Treated; TGTR – transgenic AD – Ibudilast treated.
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2.4.4

Ibudilast significantly reduces Tau PHF levels in the dentate gyrus
We used PHF1 staining (red) to analyze tau PHF levels in the hippocampus of Tg-AD rats

(Fig. 2.3A-B). Tau PHF levels were not significantly altered following treatment with IBU when
collapsed across hippocampal subregions (Fig. 3C; t = 0.4079, P = 0.6870). Regional analysis of
hippocampal subregions showed significant reduction in tau PHF levels in the dentate gyrus (DG)
(Fig. 2.3F; t = 7.295, P < 0.0001). No significant differences between treatments in CA1 (Fig.
2.3D; t = 1.419, P = 0.1688), CA3 (Fig. 2.3E; t = 0.9579, P = 0.3485), and SB (Fig. 2.3G; t =
0.2824, P = 0.7807) were identified.
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Figure 2.3: Tau paired helical filaments in the hippocampus are regionally decreased
by ibudilast treatment. Immunohistochemistry for tau paired helical filament (red, PHF1
antibody) across hippocampal subfields for (A) TGNT and (B) TGTR rats. Scale bar = 1000 µm
for (A) and (B) large panels, 200 µm for (A) and (B) small panels. Ibudilast did not affect tau
PHF1 reactivity across hippocampal subregions (C) collapsed, or in (D) CA1, (E) CA3
and (G) subiculum. (F) However, ibudilast-treatment significantly reduced tau PHF1 reactivity in
DG. Unpaired one-tail t-tests with Welch’s corrections were used in 1C through 1G. n = 12 TGNT,
n = 14 TGTR. *P < 0.05. CA1 – Cornu Ammonis; DG – Dentate Gyrus; SB – subiculum; TGNT
– Transgenic AD – Not Treated; TGTR – transgenic AD – Ibudilast treated.
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2.4.5

Effect of ibudilast on hippocampal neuronal density
Neuronal density across hippocampal subregions (CA1 and CA3 pyramidal cell layers, DG

granular cell layer, and subiculum) were assessed with NeuN staining to quantify differentiated
adult neurons. Consistent with previous studies, we observed a significant loss in NeuN signal in
the granular cell layer of DG in untreated transgenic compared to wild type rats, (unpublished
work, P < 0.01) (Fig. 2.4A, B), with corresponding masks shown in (a, b), scale bar = 1000µm.78
There is significant neuronal loss in the overall hippocampus (p = 0.04, Supplemental Table 8),
with greater neuronal loss in the granular cell layer of the dentate gyrus (p < 0.01, Supplemental
Table 8). There was no significant neuronal loss in the CA1 (p = 0.24, Supplemental Table 8),
CA3 (p = 0.18, Supplemental Table 8), or subiculum (p = 0.12, Supplemental Table 8). Neuronal
density analyzed across all hippocampal subregions was similar in IBU-treated transgenic
compared to untreated transgenic rats (Fig. 2.4C; t = 0.2237, P = 0.8250). Additional comparisons
showed no significant differences within specific pyramidal cell layers [CA1 (Fig. 2.4D; t = 1.216,
P = 0.2358) or CA3 (Fig. 2.4E; t = 1.498, P = 0.1474)], granule cell layer of DG (Fig. 2.4F; t =
1.186, P = 0.2491), or SB (Fig. 2.4G; t = 1.088, P = 0.2874).
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Figure 2.4: Effect of IBU on hippocampal neuronal density. (A) WTNT rats had significantly
higher neuronal density (NeuN staining) in the DG area compared to (B) TGNT rats, P < 0.0001.
Corresponding masks are shown in (a, b). Analysis of neuronal density between TGNT and TGTR
rats showed no significant difference in (C) the hippocampus collapsed across all
subregions, (D) CA1, (E) CA3, (F) DG, and (G) SB. Scale bar = 1000µm. Unpaired one-tail ttests with Welch’s corrections were used in 1C through 1G. n = 12 TGNT, n = 14 TGTR.
*P < 0.05. CA1 – Cornu Ammonis; DG – Dentate Gyrus; SB – subiculum; TGNT – Transgenic
AD – Not Treated; TGTR – transgenic AD – Ibudilast treated.
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2.4.6

Ibudilast specifically reduces amoeboid/ramified microglia ratio in the hippocampus
Microglia exhibit a remarkable variety of morphologies that are associated with their

specific functions. Based on shape and function (Fig. 2.5A), we considered three microglia groups
defined as follows: Ramified, actively engaged in neuronal maintenance and providing
neurotrophic factors, Reactive, responsive to CNS injury. and Amoeboid, with amorphous cell
bodies with pseudopodia that remove cell debris.59 Quantification of total microglia throughout
the hippocampus showed that there was an increase in total microglia, particularly in CA1 (F(1,47)
= 0.02; p < 0.01, Supplemental Table 9) in transgenic rats when compared to wild-type. Ibudilast
treatment remediated this region-specific increase in total microglia (F(1,47) = 5.60; p = 0.02,
Supplemental Table 9).
Microglia analysis using Iba1 staining (Fig. 2.5A) showed that in the hippocampus
collapsed across subregions, there is a significant reduction in amoeboid/ramified ratio following
IBU-treatment (F(1,51) = 13.83, P < 0.01; Fig. 2.5B) post-hoc differences between WTNT vs TGNT
(t = 4.236; P < 0.01) and between TGNT and TGTR (t = 2.746; P = 0.0491). A similar pattern was
observed in the hippocampal subregions: CA1 (F(1,51) = 4.512, P = 0.0386; Fig. 2.5C) post-hoc
differences between WTNT vs TGNT (t = 4.044; P < 0.01) and between TGNT and TGTR (t =
2.946; P = 0.0289); CA3 (F(1,51) = 6.298, P = 0.0154; Fig. 2.5D) post-hoc differences between
WTNT vs TGNT (t = 3.114; P < 0.0182) and between TGNT and TGTR (t = 2.863; P = 0.0362);
DG (F (1,51) = 16.32, P < 0.01; Fig. 2.5E) post-hoc differences between WTNT vs TGNT (t =
3.931; P < 0.01); and SB (F (1,51) = 4.167, P = 0.0464; Fig. 2.5F) post-hoc differences between
WTNT vs TGNT (t = 2.779; P = 0.0448).
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Figure 2. 5: Ibudilast treatment reduces hippocampal amoeboid/ramified microglia
ratio. (A) Microglia immunohistochemical analysis (Iba1 antibody) identified three different
types of microglia morphology expressed by specific form factor ranges for circularity.
Hippocampal amoeboid/ramified microglia ratio is significantly increased in TGNT compared to
WTNT rats, in the (B) hippocampus collapsed across all subregions, (C) CA1, (D) CA3, (E) DG,
and (F) SB. Ibudilast treatment prevented this rise in the hippocampus collapsed across all
subregions and in each individual subregion. Ordinary two-way ANOVA with Sidak’s post-hoc
tests were used in 1B through 1F. n =- 12 TGNT, n = 14 WTNT, n = 14 TGTR, n = 14 WTTR. *
P < 0.05, **P < 0.01, *** P < 0.001. CA – Cornu Ammonis, DG – Dentate Gyrus, SB – Subiculum;
WTNT – Wild-Type Not Treated; TGNt – Transgenic AD – Not Treated; WTTR – Wild-type
ibudilast treated; TGTR – Transgenic AD – ibudilast treated.
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2.4.7

Sex-dependent changes in Toll-like receptor and ubiquitin-proteasome pathway gene
expression in treated Tg-AD rats
Our RNAseq analysis reports output measures as reads per million (RPM), as well as false

discovery rate (FDR) and P values (Supplementary Table 6), and the gene expression for TGTR
is shown as percent relative to TGNT (Fig. 2.6).
Of particular interest are the effects IBU has on the mRNA expression of genes involved
in TLR signaling, since IBU is a TLR4 antagonist. Thus, we carried-out hippocampal RNA
sequencing (RNAseq) analysis of TGTR vs TGNT rats, separately in males and females (n = 5 per
condition). Genes of interest included members of the IRAK family, such as IRAK isoforms,
downstream targets of IRAK activation, and specific ubiquitin ligases and substrates (Fig. 2.6 and
Supplementary Table 6), which eventually converge on the NFkB transcription factor. Among the
16 genes of interest, five of them were unchanged in both sexes, including the adaptor MyD88,
the ubiquitin (Ub) conjugase Ube2v1, and kinases IRAK 1, 2 and 4. The remaining 11 genes were
either up or downregulated across sexes, or differentially expressed between them.
Our findings show that IBU-treatment affects gene expression levels of the TLR and UP
pathways differentially in male and female transgenic rats.
2.4.8

Sex-dependent changes in cAMP and interferon pathway gene expression in treated
Tg-AD rats
We also investigated the effects of ibudilast on gene expression with respect to cAMP and

interferon signaling pathways. The genes associated with the cAMP signaling and interferon
pathways are given in Supplemental Tables 11 (males) and 12 (females). RNAseq analyses showed
that cAMP signaling was a canonical pathway in both males and females with gene expression

43

values that were modulated significantly by ibudilast (p values < 0.5 and FDR values < 0.05).
Interestingly, ibudilast inhibition of PDEs leads to an upregulation of phosphodiesterase (PDE)
10A and cAMP specific PDE 4b and 4d as well as adenylate cyclase 1 (Adcy1) and the cAMP
dependent protein kinases Prkacb and Prkacb in females but not males. Similarly, the gene
expression for metabotropic glutamate receptors 4 (Grm4) and 8 (Grm8), which are G proteincoupled receptors, are highly upregulated by ibudilast in females. Grm4 and Grm8 are linked to
the inhibition of the cyclic AMP cascade.
Unlike the cAMP pathway, ibudilast had a modest effect on the expression of most genes
associated with interferon signaling in both males and females. Only in males, ibudilast reduced
the expression levels of the interferon lambda receptor 1 (Ifnlr1) but not significantly.
Nevertheless, genes that encode interferon regulatory factors such as Ifrd1, Ifrd2, Irf2, Irf3, Irf4
and protein kinases Prkrir and Prkra in males were modulated significantly by ibudilast (P values
< 0.05; FDR < 0.05). In females, the gene expression of interferon signaling genes that were
significantly modulated by ibudilast (P values < 0.05; FDR < 0.05) included the regulatory factors
Irf6 and Irf7 and a downregulation in interferon gamma receptor 1 (Ifngr1).
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Figure 2.6: RNA sequencing data for TGTR and TGNT rats show differential and sexdependent expression of genes involved in the toll-like receptor (TLR) and Ub-proteasome
(UP) pathways. These genes encode for IRAK-specific substrates, IRAK isoforms, and ubiquitin
ligases and conjugating enzymes. We analyzed male and female hippocampal tissues separately
for mRNA expression in TGTR relative to TGNT. The dotted red line represents 100% of the gene
expression for male or female TGNT rats. Multiple unpaired one-tail t-tests with Welch’s
corrections were used for analysis of RNA sequencing data for all genes listed in Figure 6. (n = 5
TGNT males, n = 5 TGNT females, n = 5 TGTR males, n = 5 TGTR females). *P < 0.05, **P <
0.01, ***P < 0.001, ****P < 0.0001. TGNT – Transgenic AD – not treated. TGTR – Transgenic
AD – ibudilast treated.
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2.5 . DISCUSSION
Due to the multifactorial nature of Alzheimer’s disease, conventional one-drug-one-target
approaches are unfruitful in discovering effective Alzheimer’s disease therapeutics. The low
success rate of target-based screening has revived interest in phenotypic screening based on celllines or animal models, since it could identify drug leads in physiologically relevant conditions.
However, the phenotypic screening is relatively low-throughput, expensive, and difficult in the
target deconvolution. Furthermore, drug responses in cell lines or animal models can be
significantly different from that in a patient’s tissue. The lack of mechanistic understanding of
drug actions and a knowledge gap between a model system and an individual patient, makes it
challenging to optimize drug lead compounds and to realize personalized medicine. To overcome
these challenges, we developed a new multi-scale modeling approach that bridged target-based
and phenotype-based drug repurposing. Our approach can not only use a patient’s tissue sample
directly for the phenotype-based compound screening, but also deconvolute genome-wide drugtarget interactions. We successfully identified IBU as a promising polypharmacological agent for
the treatment of Alzheimer’s disease, demonstrating the potential for integrating machine learning,
biophysics, and systems biology for the multi-scale modeling of drug actions. With the rapid
advances in machine learning, especially deep learning techniques, we can further boost the
performance of the multi-scale modeling and achieve personalized drug discovery.
We demonstrate for the first time in a transgenic rat model of Alzheimer’s disease (TgAD) that IBU-treatment mitigates cognitive deficits and hippocampal pathology associated with
Alzheimer’s disease. This transgenic rat model is unique as it exhibits hippocampal-dependent
spatial learning and memory deficits, and hippocampal Alzheimer’s disease pathology including

47

plaques, tau paired-helical filaments, neuronal loss and microgliosis, in a progressive agedependent manner that mimics the pathology observed in Alzheimer’s disease patients.37
We chose to initiate IBU-treatment at an early age (five months of age) based on previous
studies with multiple sclerosis patients showing that IBU was effective only when administered in
the early stage of the disease.46 In our studies, the long-term daily IBU-treatment (six months) was
well tolerated by the Tg-AD rats as we did not identify any adverse effects. The IBU-treatment
significantly improved spatial learning and memory and reduced Alzheimer’s disease pathology,
although some of the Alzheimer’s disease-pathology was still detectable albeit at significantly
lower levels. Overexpression of the human APPsw (2.6-fold) and PS1DE9 (6.2-fold) driving the
robust pathology, may account for the incomplete protection provided by IBU.
The preventive effects of IBU-treatment that we observed in the Tg-AD rats, were most
prominent in the dentate gyrus (DG) region of the hippocampus, a regional effect of IBU that
remains to be investigated. However, since the DG is known to be vulnerable to aging and to be
affected in the early stages of Alzheimer’s disease it is possible that the DG is also the most
responsive to treatment.79 80 Overall, our data clearly demonstrate the potential of IBU to lessen
deficits in spatial learning and memory, to mitigate plaque and tau PHF pathology, and to diminish
gliosis in the hippocampus of the Tg-AD rats. IBU treatment did not remediate the decrease in
differentiated neurons observed exclusively in the DG granular cell layer of the Tg-AD rats.
Notably, the cognitive deficits of Tg-AD rats were significantly improved following IBU
treatment. This significant improvement could be mediated by several compensatory mechanisms
induced by IBU-treatment, such as (1) increased cerebral blood flow, (2) reduction in
neuroinflammation, (3) promotion of neurotrophic factors, (4) enhanced synaptic plasticity, or
other alternative mechanisms, all of which will be addressed in future studies.45,81
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Our

RNAseq analyses shows that IBU treatment: (1) Reduces inflammation by decreasing the levels
of the pro inflammatory cytokine IL6, interferon receptor 1, the macrophage migration inhibitory
factor (MIF), microglial associated proteins such as transmembrane protein 119 (TMEM119),
arachidonate 5-lipoxygenase activating protein (Alox5ap), toll like receptor 7 (TLR7), lysosomal
protein transmembrane 5 (LAPTM5), and triggering receptor expressed on myeloid cells 2
(TREM2). (2) Increases expression of synaptic proteins such as synaptotagmin 2 (SYT2) which
regulates vesicular transport, syntaxins (STX) which participates in neurotransmitter release, and
cadherin (CDH1) which maintains synapse structure. (3) Reduces the expression of the
neurotrophic factor BDNF by 2-fold in both male and female treated rats. These findings suggest
that IBU provides neuroprotection independent of growth factor upregulation. Furthermore,
inhibition of TLR4 and the reduction in proinflammatory factors by IBU-treatment supports its
benefits on cerebral blood flow. The RNAseq data were further evaluated by performing an
unbiased Gene Ontology (GO) enrichment analyses (Supplemental Figure 5). In these analyses
changes in the transcript levels of TGTR male and female rats versus TGNT rats were organized
and prioritized according to their function and relationships. The Ingenuity Pathway analysis (IPA)
summary lists the canonical pathways most affected by IBU-treatment in TGTR male and TGTR
female rats (Supplemental Table 10).
A previous study in mice supported the preventive effects of 15 days of IBU-treatment
(i.p.) prior to receiving bilateral intracerebroventricular injections of Aβ1–42.85 IBU-treatment
significantly ameliorated spatial learning and memory deficits and decreased hippocampal
neuroinflammatory and apoptotic responses in the Ab-injected mice. In an MPTP mouse model of
Parkinson’s disease, IBU was administered subcutaneously b.i.d. for 9 days, starting two days prior
to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication.86 IBU diminished
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astroglial activation in the MPTP-treated mice but had no impact on striatal dopaminergic cell
survival seven days after acute MPTP intoxication. These two mouse studies evaluated the efficacy
of a short-term IBU-treatment, in contrast to our studies that evaluated the effects of a long-term
IBU-treatment using a transgenic rat model of Alzheimer’s disease that exhibits progressive agedependent pathology. This is important because Alzheimer’s disease is a progressive
neurodegenerative disorder with aging being the greatest risk factor. Thus, it is critical to evaluate
the long-term effects of potential therapeutics.
IBU was first described as a non-specific PDE inhibitor, but more recently was shown to
also act as a TLR4 antagonist.51 52-54,86,87 IBU crosses the blood brain barrier, has a half-life of
about 19 hours, improves blood flow to the brain, and protects against neuroinflammation.81 The
anti-inflammatory effects of IBU could be mediated by its PDE-inhibiting properties or by its
TLR4 inactivation, and it is unclear which property potentiates the other, or if both work in
synchrony. IBU-treatment exhibited immunomodulatory effects in multiple sclerosis and
amyotrophic lateral sclerosis by shifting the pro-inflammatory phenotype of microglia to an antiinflammatory phenotype.17 88 Based on these findings, we propose that the beneficial effects of
IBU observed in our studies can be attributed, in part, to the anti-inflammatory effects of IBU.
The RNAseq analysis revealed that the TLR and UP pathways are differentially altered by
sex following IBU-treatment of the Tg-AD rats. We know from the literature that there are gender
differences in TLR signaling with respect to pain, chronic fatigue, and immune response.89 90 91
However, we found no reports that TLR signaling is differentially affected with respect to gender
in Alzheimer’s disease. To the best of our knowledge, the sex differences observed in our RNAseq
data are novel findings that have not been reported. We will discuss two potential mechanisms that
could mediate the anti-inflammatory action of IBU on the TLR pathway. For example, IBU-
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induced up-regulation of IRAK3, a central negative regulator of TLR signaling that prevents
IRAK1 from activating TRAF6 through phosphorylation, thus preventing NFkB activation.
Furthermore, the TLR pathway is dependent on the function of the UP pathway at several steps,
such as (1) degradation of IRAK1 after phosphorylation of TRAF6, (2) degradation of TRAF6
after activation of the TAK/TAB complex, and (3) degradation of IkB, which is required for NFkB
nuclear translocation and activation. IBU-induced alterations on the expression of genes coding
for components of the UPP, as shown in our data, indicate that this degradation pathway is
recruited for modulation of inflammation via the TLR pathway.
Our study shows that six months of ibudilast treatment delivered orally, mitigates the
progressive AD pathology observed in 11 month old Tg-AD rats. However, there are certain
limitations that warrant further investigation. For example, (1) Our experimental design addresses
how IBU treatment could be useful in prevention of the AD pathology. Future studies are needed
to determine the effects of IBU on slowing or mitigating AD pathology in its advanced stages. (2)
Our analysis focused on characterizing the learning and memory deficits in the Tg-AD rats but did
not fully characterize the impact that anxiety plays on spatial learning and memory. (3) While our
results demonstrate that inhibiting the targets of IBU is sufficient to reverse several Alzheimer’s
phenotypes in transgenic rats, additional experiments are needed to determine whether it is
necessary to inhibit all the targets simultaneously, or whether the same effect can be achieved with
a smaller subset.
In Japan and other Asian countries, IBU is approved for treating asthma and stroke.92 Based
on our results, the outcome and details of the IBU-induced alterations in the TLR and UP pathways
will be addressed in future studies. However, their significance is crucial as IBU is a TLR4
antagonist. Interestingly, TLR4-mediated induction of apoptosis is observed mostly in aging and
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not young neurons.93 TLR4 mediated signaling, via still unclear mechanisms, seems to contribute
to the pathology of age-related neurodegenerative diseases, including Alzheimer’s disease.93 Using
TLR4 antagonists, such as IBU, could offer an efficient means to prevent the damaging events
associated with neuroinflammation in Alzheimer’s disease. Overall, our results support that IBU
can be repurposed as a potential therapeutic to treat memory deficits and pathology in Alzheimer’s
disease.
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3.1 ABSTRACT
The multifactorial nature of AD, such as the development of Ab plaques, neurofibrillary
tau tangles, neuroinflammation, and cognitive decline that ensues has been on the mind of many
investigators regarding the design of therapeutics. Attempts to study the disorder have led to many
questions regarding diagnosis, treatment, and prevention, likely due to the ongoing discovery of
signaling pathways, such as the TLR signaling pathway, that are differentially regulated in AD
compared to healthy aging. Investigators have studied the human genome to determine if there are
genetic predispositions that predict if someone will develop AD. Successes were reported curbing
the severity of other neurodegenerative disorders when early intervention strategies are
implemented, such as MS and Parkinson’s, although their successes are limited to symptom
management.
The TLR pathway plays an important role in the regulation of the inflammatory response
in innate immunity. Its normal function contributes to the return to homeostasis when the
inflammatory stimulus is cleared. In AD, TLR signaling is dysregulated in relation to healthy aging
due to the abnormal presence of dead cells, Ab, and other pro-inflammatory mediators. The longterm presence of extracellular stimuli in AD causes the pro-inflammatory response initiated by
glial cells and the TLR pathway to become chronic, culminating in neurodegeneration and
neuronal cell death.
Studies with post-mortem human AD brains detected glial cell increases and neuronal cell
decreases compared to healthy-aged brains, suggesting a relationship between increased TLR
activity in overly abundant immune cells and decreased neuronal cell viability. Post-mortem
studies show inconsistencies in TLR distribution and levels between human AD brains and brains
from mouse models of AD. Although TLR signaling proceeds similarly in both organisms, there
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are some differences in how the mechanisms are initiated due to the genomic differences between
humans and mice. These findings suggest that future investigations using animal models should
show translational relevance and show reproducibility in human samples to be considered
significant and warrant further investigation
Keeping this discrepancy between the human and mouse genome in mind, I investigated
published literature comparing different TLR distribution and levels in mouse and human brains,
as they could affect the predicted efficacy of drugs, such as IBU to treat neuroinflammation in AD.
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3.2. INTRODUCTION
Genetic risk factors for AD account for less than 1% of all cases, as most cases are sporadic
late-onset AD.94 Problems investigators, clinicians, and pharmaceutical companies have faced in
recent years are the development of therapeutics and mitigation strategies that either (1) target only
one aspect of the disease pathology (such as plaques or tangles) or (2) treat patients when they
already exhibit the cognitive decline.95 In past clinical trials, most recently, the 2021 approval of
aducanumab that targets Ab plaques, the use of pharmaceutical compounds that are designed to
target one AD hallmark, have shown no beneficial effects on halting disease progression.96
The brain is responsible for a plethora of functions, not limited to mechanical movement
of the body, control of thought, memory, and essential functions, but also maintaining autonomous
control over these functions.97 When all these processes act in concert, adapting to small variations
in the extracellular environment to maintain optimal functioning conditions, the body is in a state
of homeostasis. With respect to the brain, maintenance of homeostasis is carried out mainly by the
immune cells, such as the microglia and astrocytes.98
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Together, their function includes

maintaining neuronal cell integrity, synaptic plasticity, uptake, and recycling of neurotransmitters,
and engaging in the resolution of pro-inflammatory stimuli when in the presence of cellular debris
and foreign toxic substances.
Microglia and astrocytes, along with other cell types, exhibit TLRs on their plasma
membranes, which are responsible for initiating the inflammatory response in the presence of
extracellular factors that serve as homeostatic disruptors.
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Figure 3.1: A brief schematic representation of the M1 / M2 microglia polarization. Microglia
are classified as either M1 or M2 based on their cytokine and chemokine profiles. Resting state
microglia adopt one of the two phenotypes based on environmental factors and secreted cytokines.
The presence of PAMPS and DAMPS disrupts homeostasis. When PAMPS or DAMPS bind to
their respective TLR on the plasma membrane of microglia, they will induce a shift of microglia
towards an M1 phenotype, leading to the production of more pro-inflammatory cytokines, reactive
oxygen species, and inducible nitric oxide synthase. However, when the extracellular matrix
predominantly contains anti-inflammatory cytokines, the microglia will shift toward an antiinflammatory M2 phenotype, leading to production of additional anti9-inflammatory cytokines
and growth factors.
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3.3. GLIOSIS AND ALZHEIMER’S DISEASE
As one of the resident immune cells of the brain, microglia cells are responsible for the
maintenance of homeostasis through the scouting and elimination of insults, ranging from cellular
debris to toxic foreign particles by way of immune cell recruitment and subsequent phagocytosis.100
In their role of maintenance, microglia in the brain exhibit distinct phenotypes; ramified, reactive,
and amoeboid.59
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In the ramified resting state (roughly 85-90% of all microglia under

homeostatic conditions), microglia are responsible for the maintenance of synaptic plasticity,
modulation of cognitive functions such as learning and memory, and the maintenance of brain
homeostasis through secretion of neurotrophic factors. Also in the ramified state, microglia scout
the surrounding environment for signs of cellular debris or foreign particles. The shift in microglia
towards a more reactive phenotype occurs in the presence of stimuli, such as cellular debris or
toxic foreign substances. Normally about 5-8% of total microglia are in the reactive phenotype.
However, more ramified microglia adjacent in the adjacent area to the stimulus can shift to reactive
microglia upon secretion of pro-inflammatory mediators, such as cytokines and chemokines,
indicating a disruption to homeostasis. At this point, some microglia shift into an amoeboid
phenotype (roughly 2-5% under homeostatic conditions), which will actively engage in
phagocytosis to clear the insult. Upon removing the cellular debris, microglia will release antiinflammatory mediators and revert to their resting state phenotypes and restore homeostasis.
Some investigators have classified this transformation in microglia to a binary M1 proinflammatory microglia vs M2 anti-inflammatory microglia phenotype. The difference between
the M1 and M2 phenotypes focuses on the cytokines that are predominantly released by the
respective cells, with M1 microglia secreting pro-inflammatory cytokines such as TNFa, IL-6, and
IL-1-b as well as reactive oxygen species (ROS).102 Alternatively, M2 microglia predominantly
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secret anti-inflammatory cytokines and neurotrophic factors such as BDNF, TGFb, IL-10.103
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The problem is that although microglia are responsible for maintaining a stable extracellular
environment in the brain, it is the prolonged activation of these M1 signals in the long-term face
of Ab plaques and other pro-inflammatory mediators, that leads to neuronal cell damage.
Post-mortem human AD brain studies showed that there are increased levels of activated
microglia particularly around Ab plaques.105 This finding suggests that Ab can be considered one
of the toxic triggers that microglia detect and interpret as a disruptor of homeostasis.106
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In

addition to finding increased activated microglia, post-mortem AD brain studies found an increase
in pro-inflammatory cytokines and other factors, indicating prolonged microglia activation.
Evidence to support this finding also includes a reduction in the number of neuronal cells.
Astrocytes, like microglia, are responsible for the maintenance of brain homeostasis. Its
role in maintenance is centered around the recycling of neurotransmitters, release of
gliotransmitters and nutrients, and regulation of synaptic activity.108 Also, astrocytes can exhibit a
pro-inflammatory A1 and anti-inflammatory A2 phenotype, therefore releasing phenotypedependent cytokines similarly to microglia. Similar to the increased presence of microglia in AD
brains, there is an increased number of reactive astrocytes in the human AD brain, suggesting that
persistent inflammation observed in the brain is caused by the pro-inflammatory response
generated by both cell types.

3.4. VARIATION BETWEEN HUMAN AND MOUSE TOLL-LIKE RECEPTOR
DISTRIBUTION AND LEVELS RELEVANT TO ALZHEIMER’S DISEASE
TLRs are membrane-bound proteins that are activated in the presence of PAMPS or
DAMPS through an extracellular domain, generating a pro-inflammatory response.109

60

110

Compared to mouse models that have 13 documented types of TLR’s, humans have been so far
documented in having 10 distinct TLRs.111 The distribution of TLRs among cell types differs, with
neurons and microglia expressing the widest variety of TLRs: TLRs 1-10 for neurons, TLRs’ 1-9
for microglia, TLR’s 1-5 and TLR9 for astrocytes, and oligodendrocytes containing only TLRs 2
and 3.112
Brain samples of AD patients exhibit higher levels of TLR mRNA expression across all
variants except for TLR2 mRNA than healthy aged brains.113 114 115 Considering that each TLR has
a set of compatible substrates, it makes sense that the inflammatory response generated from
activation of various combinations of TLRs differs (example: TLR2 and TLR4 vs. TLR2 alone).115
Despite mouse models relating TLR7 upregulation with autophagy, human AD brain studies on
TLR7 have not shown that correlation, leading to the speculation that TLRs play roles outside
inflammation and neurodegeneration. This hypothesis is supported by a previous study on postmortem AD brains that suggests that there is great variation in TLR expression between patients.
A comparison study between whole tissue mouse brains and those of human AD brains
found that while there are some correlations between TLR levels in mouse and human’s brain
tissue, there are deviations in expression under AD conditions, as for example: (1) TLR1 levels in
mice increase while human brains showed no change, and (2), TLR8 levels in mice did not show
differences, while human brains showed an increase.116 More interesting are the differences
observed in TLR expression for AD studies between mouse cells and human tissue, with almost
all TLR studies showing contrasting results, apart from TLR2. Mouse studies reported decreases
in TLRs 3-6 and TLR9, and increases in TLRs 1 and 2, while human studies reported upregulation
of all TLRs except for TLR1, exemplifying the gaps in development of AD between nonhuman
rodents as well a cellular models derived from non-humans, and human tissue studies.115
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A study utilizing CNS cells from AD patient brains found that microglia exhibited
detectable levels of TLRs 1-9, while for astrocytes and oligodendrocytes, TLRs 2 and 3 were
detected.117 IHC studies with CD68+ microglia cells showed that TLR3 and TLR4 were localized
to intracellular vesicles, suggesting that TLRs were likely stored in these structures and recruited
to the endosome. However these TLRs were exclusively found on the cell surfaces of astrocytes.118
Overall, it is critical to have a full understanding of the localization and levels of TLRs in the
human and mouse brain, to more efficiently develop drugs that target those receptors to treat
neuroinflammation in AD.

4.5. CONCLUSION
Studies performed in human brain cells and tissues showed that TLR distribution and
expression levels deviate from those in nonhuman rodent models of AD. Mice, for example
express three additional TLRs not documented in humans, while the expression levels of individual
TLRs deviates by cell type.
The TLRs signal transduction pathways do appear to be common among humans and nonhuman animals. TLRs are for the most part, activated under stress conditions, either by PAMPS
or DAMPS, converging on the production of pro-inflammatory mediators, such as IL-6, IL-13,
and TNFa.112
Thoroughly understanding the TLR differences between human and mouse brains is critical
to the prediction of drug efficacy translatable from mouse to human. Moreover, understanding the
role of glial cells and how they pertain to AD progression is also of clinical significance since it is
believed that increased activation of the M1 microglia and A1 astrocyte phenotype contributes to
inflammation and neuronal detected in AD.
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CHAPTER IV – DIAZOXIDE/DIBENOZYLMETHANE CO-TREATMENT
ATTENUATES PATHOLOGY IN A TG-AD RAT ALZHEIMER’S MODEL

Giovanni Oliveros

Department of Biology
Hunter College of the City University of New York
New York, New York 10065

NOTE: The effects of the DZ/DIB co-treatment on Tg-AD rats was complemented by studies
carried-out by another graduate student in our laboratory, Charles Wallace. Charles investigated
the effect of the double drug treatment on spatial-working memory performance using the radial
8-arm maze. His data are not discussed here.
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4.1 ABSTRACT
AD is a multifactorial disease characterized by Ab plaques, neurofibrillary tau tangles, and
neuroinflammation in the brain, leading to cognitive deficits in patients. Therefore, efficacy of
treatment is dependent on a multitarget drug approach. To this end, we utilized a combination drug
treatment of diazoxide (DZ) and dibenzoylmethane (DIB) to combat Alzheimer’s due to their
promising effects on attenuating neurodegeneration and apoptosis. DZ treatment has shown
promising effects in reducing neuronal loss and microglial activation in adult male Wistar rats
inflicted with an N-methyl-D-aspartate (NMDA)-induced hippocampal injury compared to
untreated rats through activation of potassium-ATP (KATP) channels. DIB has previously shown
promising effects on inhibiting the unfolded-protein response (UPR) through eIF2a signaling,
preventing neurodegeneration. Although previous studies have examined individual therapeutic
benefits of these treatments in other animal model systems, their combined therapeutic potential
has yet to be studied. We utilized the Tg-AD Fisher TgF-344AD rat model of AD (Tg-AD), which
expresses human mutant “Swedish” amyloid-precursor protein (APPsw) and ∆ exon 9 presenilin
1 (PS1 ∆E9) to test the efficacy of this treatment. Tg-AD rats exhibit age-dependent development
of Ab plaques, tau paired-helical filaments, neuronal loss, microgliosis, and cognitive deficits,
mimicking the progression of AD in humans more closely compared to other model systems.
Following long-term DZ/DIB treatment, I assessed by IHC its ability to mitigate the progression
of AD pathology. I found that DZ/DIB treatment reduced the buildup of Ab plaques and
neurofibrillary tau tangles in the hippocampal DG region compared to age-matched untreated TgAD rats. DZ/DIB treatment did not prevent the increase in gliosis or neuronal loss. However, the
combined treatment decreased the levels of eIF2-a in the hippocampus, suggesting a decrease in
abrupt termination of protein synthesis in neurons.
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In addition, our RNA sequencing analysis of a subset of 4-month untreated female Tg-AD
rats compared to WT controls, revealed two potential early biomarkers for AD, i.e. EGR2 (early
growth response 2) and HISIT1H2AA (histone H2AA) genes.
Overall, our results suggest that treatment with DZ/DIB can have therapeutic benefit
against AD progression due to its multitarget approach involving multiple signaling pathways.
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4.2 INTRODUCTION
AD is the most common form of dementia and has become a growing concern among the
aging population.1 Most current AD intervention strategies only targets one aspect of the
pathology.119,120 This single-target approach (either targeting plaques or tangles) has led to the
most current AD drugs on the market to fail in halting disease progression. Most recently the 2021
drug aducanumab reduces Ab plaque buildup but has no benefit in improving cognition in clinical
trials.96 Attention is now being directed to the use of multitarget therapies that do not exclusively
focus on plaques and tangles, but also address neuronal loss caused by inflammation related to the
production of reactive oxygen species and pro-inflammatory mediators.150
Considering that the timeline from initial drug design to oral availability spans many years
due to the need for pre-clinical animal studies, cytotoxicity studies, and human clinical trials to
study efficacy, there is a growing need to optimize this timeline.120 Our approach to condense the
timeline and optimize AD therapeutic approaches was to utilize a drug-reproposing bioinformatics
approach to explore the off-target effects of current FDA-approved drugs.13 This strategy bypasses
the need to design pharmaceuticals de novo and establish ideal concentration curves to address
cytotoxicity problems, allowing us to consider the beneficial off-target effects of pharmaceuticals,
such as neuroprotective effects and regulation of inflammatory signaling pathways.
We decided to investigate the beneficial effects of a DZ/DIB combination treatment for
AD due to their previous successes in attenuating neurodegeneration in rodent models. DZ is a
benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine and functions to reduce
hypertension and hyperglycemia. DZ functions by increasing membrane permeability to potassium
ions in vascular smooth muscle, stabilizing the membrane action potential and leading to
vasodilation. Previously, DZ has been shown to protect NSC-34 motoneurons from glutamatergic,
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oxidative, and inflammatory damage.121

122

DIB is a 1,3-diketone prepared from condensation of

ethyl benzoate with acetophenone yet exists in a keto-enol tautomeric form. A previous
investigation showed DIB to prevent eIF2-a activation and prevent premature protein synthesis in
neurons.123 While DZ and DIB individually show promise in mitigating neurodegeneration, their
combined therapeutic potential has yet to be tested.
We utilized the Tg-AD rat model to assess the effect of combination DZ/DIB treatment in
Tg-AD rats and age-matched WT littermates. The age-dependent progression of AD pathology
observed in this rodent model makes it an optimal model for our studies.
I assessed AD pathology in 4-month (pre-pathology) and 11-month-old (moderate
pathology) DZ/DIB treated Tg-AD and WT rats, and compared them to untreated age-matched
littermates. Treatment started at six weeks of age. As expected, at 4 months of age the Tg-AD rats
did not exhibit Ab plaques, neurofibrillary tau tangles, gliosis or neuronal loss, and DZ/DIB
treatment had no effect on these rats. At 11-months of age untreated Tg-AD rats exhibited
significant AD pathology compared to untreated WT rats.50 Notably, the DZ/DIB treatment
reduced the buildup of Ab plaques and neurofibrillary tau tangles in the hippocampal DG region
compared to age-matched untreated Tg-AD rats. DZ/DIB treatment did not prevent the increase in
gliosis or neuronal loss. Notably, using RNA sequencing analysis of a subset of 4-month untreated
female Tg-AD rats compared to WT controls, revealed two potential early biomarkers for AD, i.e.
EGR2 and HISIT1H2AA genes.
In conclusion, DZ/DIB treatment mitigated some of the AD pathology in aged rats,
supporting its potential as an AD therapeutic. We also identify two novel early biomarkers that
could be used in future AD diagnosis.
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4.3 MATERIALS AND METHODS
4.3.1 Fisher TgF-344AD (Tg-AD) rat model of AD – described in Chapter 1, section 1.2.3 and
Chapter 2, section 2.2.1
4.3.2. DZ/DIB combination treatment
A total of 54 rats [WT n = 30 (15 females, 15 males), Tg-AD n = 24 (10 females, 14 males)]
were used in the IHC and RNAseq analyses for the DIB/DZ study. At 52 days of age, Tg-AD rats
began a combination DZ/DIB treatment regimen (DZ - 10 mg/kg bw and DIB - 200 mg/kg bw).
Age-matched untreated controls were fed DZ/DIB free rodent chow. DZ/DIB treated WT and TgAD

4.3.3 Immunofluorescence (4 Months and 11 Months) – Described in Chapter 2, with one
addition: GFAP for astrocytes (Invitrogen – rabbit – cat number PA1-10019, 1:500 dilution)

4.3.4 Western blot analysis for APP, EGR2, eIF2-alpha and caspase 3
Antibodies used for this study included APP A4 (clone 22C11, mouse, cat number –
MAB348, Millipore, 1:10000 dilution), EGR2 (Abcam, rabbit, cat number # 43020, 1:10000
dilution), eIF2a (cell signaling, mouse, cat number #2103S, 1:1000 dilution), caspase 3 (cell
signaling, mouse, cat number # 9662, 1:1000 dilution).

Hippocampal tissue was homogenized in a TBS solution containing protease and
phosphatase inhibitors and 1% EDTA for 45 seconds at 25OC with a beadbug microtube
homogenizer (3400 rpm, model D1030, Benchmark Scientific). The supernatant was stored
overnight at -80OC until use. Protein concentration was determined with the BCA assay (Pierce
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Biotechnology), followed by normalization. For APP and EGR2 samples, 40µg from each sample
(for eIF2-a, caspase 3, and b-tubulin; 10µg from each sample for APP, EGR2, and b-actin) were
run on 4-20% NOVEX Tris-Glycine gels and transferred to nitrocellulose membranes using an
iBlot dry blotting system (Life Technologies for 7 minutes. Membranes were blocked with
SuperBlock (cat number 37535, Thermofisher), and hybridized with either APP, EGR2, eIF2-a,
caspase 3, b-tubulin, or b-actin, followed by HRP-conjugated secondary antibodies prior to
developing with an enhanced chemiluminescence (ECL) substrate (supersignal ™ West Pico
PLUS, ThermoFisher #34580), and detected on a BX810 autoradiography film (Midwest
Scientific). ImageJ software (Rasband, W.S., ImageJ, U.S. National Institutes of Health, Bethesda,
Maryland, USA, https://imagej.nih.gov/ij/, 1997-2018) was used for semi-quantification by
densitometry of the respective bands. Loading controls used were b-tubulin or b-actin depending
on the protein’s molecular weights to avoid overlapping with other proteins studied.

4.3.5 Statistical Analysis – described in Chapter 2, section 2.3.3.4 with one addition.
For western blot analysis, a mixed model three-way ANOVA was first used along with
Tukey’s post-hoc analysis to measure differences in band intensity in all measured samples across
two age points (4 months and 11 months), two genotypes (WT and Tg-AD), and drug treatments
(combination DZ/DIB treatment versus no treatment). Then an ordinary two-way ANOVA was
performed with Tukey’s post-hoc analysis to determine the effects of DZ/DIB treatments within
each respective age group, still considering the effects of treatment and genotype on protein levels.
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4.4 RESULTS
4.4.1 DZ/DIB treatment significantly reduced tau PHF1 levels in the hippocampal CA3 and
DG regions in 11-month Tg-AD
Tau PHF1 levels in the overall hippocampus when collapsed across regions (Figures 4.1A
and 4.1.B) were not significantly reduced following DZ/DIB treatment (Figure 4.1.C, t = 1.358, p
= 0.19). However, significant regional reductions were detected in CA3 (Figure 4.1.E, t = 2.299,
p = 0.03) and DG (Figure 4.1.F, t = 2.958, p < 0.01) PHF1 levels. No significant reductions in
PHF1 signal were detected in CA1 (Figure 4.1.D, t = 0.3327, p = 0.74) or the SB (Figure 4.1.G, t
= 0.6657, p = 0.52). We did not look at tau PHF1 levels in 4-month-old Tg-AD rats since prior
reports showed no accumulation of PHF1 until 16 months of age.50 (detected with anti-PHF1
antibody, generously donated by Peter Davies)
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Figure 4.1: By 11 months, DZ/DIB treatment reduced accumulation of Tau paired helical
filaments regionally. 11-month-old TG-AD rats IHC for tau PHF1 across hippocampal regions
for (A) TGNT vs. (B) TGTR rats at 11 months of age. Scale bar = 1000µm for large panels, Scale
bar = 100µm for small panels. At 11 months, DZ/DIB treatment did not cause a significant
reduction in PHF1 levels in the overall hippocampus (C), nor in CA1 (D) or the SB (G) of Tg-AD
rats. 11-month DZ/DIB treated Tg-AD rats exhibited significant reductions in PHF1 levels in CA3
(E) and in DG (F) compared to age-matched not-treated Tg-AD controls. Unpaired one-tailed ttests with Welch’s corrections were used in panels 2C through 2G. *p < 0.05, **p < 0.01. n = 10
TGNT, n = 10 TGTR. TGNT = Tg-AD not treated. TGTR = Tg-AD DZ/DIB treated. CA = cornu
ammonis, DG = dentate gyrus, SB = subiculum. PHF = paired helical filaments
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4.4.2 DZ/DIB treatment significantly reduced Ab plaque levels in the DG hilar region of 11month Tg-AD rats
4-month-old TG-AD rats did not develop Ab plaques independently of drug treatment (not
shown). However, I detected significant Ab plaque buildup in 11-month-old Tg-AD rats (Figures
4.2A and 4.2B) DZ/DIB treatment did not reduce the buildup of Ab plaques throughout the
hippocampus when collapsed across subregions (Figure 4.2.C, t = 0.0798, p = 0.94). In addition,
no significant attenuations in Ab plaque buildup were observed in the CA1 (Figure 4.2.D, t =
1.611, p = 0.13), CA3 (Figure 4.2.E, t = 0.3037, p = 0.77), DG (Figure 4.2.F, t = 1.159, p = 0.26),
or the SB (Figure 4.2.G, t = 0.397, p = 0.70) of 11-month DZ/DIB treated Tg-AD rats. In contrast,
subregion analysis within the DG showed that the hilar region exhibited significant reductions in
Ab plaque load (Figure 4.2.H, t = 2.140, p = 0.05) in 11-month DZ/DIB treated Tg-AD 11-month
compared to untreated age-matched Tg-AD controls.
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Figure 4.2: DZ/DIB treatment reduced Ab plaque burden in the DG hilar subregion of 11month Tg-AD rats. IHC analysis for Ab (detected with the anti-Ab 4G8 antibody) across
hippocampal subregions for (A) TGNT vs. (B) TGTR rats at 11-months of age. Scale bar =
1000µm. At 11 months, DZ/DIB treatment did not significantly reduce Ab plaque loads in the
overall hippocampus (C), nor in the main regions CA1 (D), CA3 (E), DG (F) or the SB (G) of TgAD rats. Ab levels were significantly attenuated in the DG hilar subregion with DZ/DIB treatment
(H) when compared to age-matched not-treated Tg-AD controls. Unpaired one-tailed t-tests with
Welch’s corrections were used in panels 2C through 2G. *p < 0.05, **p < 0.01. n = 10 TGNT, n
= 10 TGTR. TGNT = Tg-AD AD not treated. TGTR = Tg-AD AD DZ/DIB treated. CA = cornu
ammonis, DG = dentate gyrus, SB = subiculum.
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4.4.3 DZ/DIB treatment did not have a significant impact on reducing neuronal loss
Tg-AD rats exhibit neuronal loss at 11 months of age across the entire hippocampus (Figure
4.3C), particularly in the DG granular cell layer (GCL) (Figure 4.3H), but not at 4-months of age
(not shown): CA1 (Figure 4.3.D, F(1,35) = 4.999, p = 0.03), CA3 (Figure 4.3.E, F(1,35 = 5.046, p =
0.03), DG (Figure 4.3.F, F(1,35) = 10.14, p < 0.01), SB (Figure 4.3.G, F(1,34) = 17.36, p < 0.001), GCL
(Figure 4.3.H, F(1,35) = 35.92, p < 0.0001) IHC analysis at 11 months of age showed that DZ/DIB
treatment did not significantly reduce neuronal loss. Post-hoc differences were observed within
the SB between WTTR and TGTR rats (Figure 4.3.G, p < 0.01, and in the GCL (Figure 4.3.H, p <
0.001 for WTNT vs. TGNT, p < 0.01 for WTTR vs. TGTR).
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Figure 4.3 DZ/DIB treatment did not mitigate neuronal loss in 11-month Tg-AD rats. IHC
analysis for NeuN (Millipore, cat # ABN91), a neuronal marker. At 4-months I did not detect any
changes (not shown) At 11 months, Tg-AD not-treated rats exhibit significant neuronal loss
compared to wild-type not-treated rats (Figure 4.3.A and 4.3.B) in the overall hippocampus (C),
and in the CA1 (D), CA3 (E), DG (F), SB (G), and GCL (H). DZ/DIB treatment did not reduce
the extent of neuronal loss shown by Tg-AD rats. Ordinary two-way ANOVA with Sidak’s posthoc analysis were used. *p < 0.05, **p < 0.01, ***p < 0.001. n = 10 WTNT, n = 10 TGNT, n = 10
WTTR, n = 11 TGTR. WTNT = Wild-type not treated, TGNT = Tg-AD AD not treated, WTTR =
Wild-type DZ/DIB treated, TGTR = Tg-AD AD DZ/DIB treated. CA = cornu ammonis, DG =
dentate gyrus., SB = subiculum, GCL = granular cell layer.
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4.4.4 – DZ/DIB treatment had no effect on microgliosis
Microglia exhibit three distinct morphologies; ramified, reactive, and amoeboid. (Figure
4.4.A).59 I performed IHC for microglia and their three morphologies on 4-month and 11-month
rat hippocampi. There were no significant increases in microgliosis in TGNT rats compared to
WTNT rats at 4 months of age (not shown). By 11 months, there was a significant increase in
microgliosis in the hippocampus collapsed across subregions and across treatments in Tg-AD
versus WT rats, assessed by ordinary two-way ANOVA (Figure 4.4.B, F(1,34) = 17.08, p = 0.0002),
with Sidak’s post-hoc differences observed between WTNT and TGNT rats (p = 0.01). We found
hippocampal subregion specific (CA1, CA3, DG, and the subiculum) increases in total microglia
in transgenic rats, collapsed across treatment, yet DZ/DIB combination treatment did not attenuate
this increase in gliosis (Supplemental Table 4.1 through 4.4). Dividing the microglia by their
respective phenotypes, we found that collapsed hippocampal microglia analysis shows transgenic
rats exhibiting increased levels of ramified (Figure 6C, F(1,34) = 7.673, p = 0.009), reactive (Figure
6D, F(1,34) = 18.95, p = 0.001), and amoeboid microglia (Figure 6E, F(1,34) = 28.19, p < 0.0001) when
compared to wild-type and collapsed across treatments. Sidak’s post-hoc tests showed differences
in reactive (Figure 6D, p = 0.0001 for WTNT vs. TGNT) and amoeboid microglia (Figure 6E, p =
0.006 for WTNT vs. TGNT and p = 0.002 for WTTR vs. TGTR). Hippocampal subregion specific
differences in phenotypically unique microglia levels were also found between wild-type and
transgenic rats yet DZ/DIB did not significantly attenuate these increases (tables 4.1 through 4.4).
I also assessed astrocyte levels in Tg-AD and WT rats at both 4 months and 11 months of age
using the GFAP antibody and saw no significant differences in GFAP expression (not shown).
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Figure 4.4: At 11 months of age, Tg-AD rats compared to WT controls exhibit increased
microglial levels, while DZ/DIB treatment fails to significantly reduce the extent of
microgliosis. IHC analysis showed that microglia exhibit three distinct morphologies (ramified,
reactive, and amoeboid) (A). At 11 months, transgenic not-treated rats exhibit significant
microgliosis (B) when compared to wild type, regardless of treatment. The increase in gliosis is
observed across the different microglia morphologies, with transgenic rats showing increased
levels of ramified microglia (C), reactive microglia (D), and amoeboid microglia (E) compared to
wild-type. DZ/DIB treatment did not attenuate this increase in microgliosis. Ordinary two-way
ANOVA with Sidak’s post-hoc analysis was used in panels B through E. *p < 0.05, **p < 0.01. n
= 10 WTNT, n = 10 TGNT, n = 10 WTTR, n = 11 TGTR. WTNT = Wild-type not treated, TGNT
= transgenic AD not treated, WTTR = Wild-type DZ/DIB treated, TGTR = transgenic AD DZ/DIB
treated.
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Morphology

WT untreated

Tg-AD untreated

WT DZ/DIB Treated

Tg-AD DZ/DIB Treated

mean + SEM

mean + SEM

mean + SEM

mean + SEM

p-value

F(DFn, DFd)

< 0.01 (g) F (1,34) = 23.70 (g)
Total Microglia

2.59E-04 + 4.17E-06

3.27E-04 + 2.25E-05

2.65E-04 + 2.90E-06

3.28E-04 + 1.45E-05

Ramified

2.42E-04 + 4.30E-06

2.76E-04 + 1.79E-05

2.47E-04 + 4.27E-06

2.83E-04 + 1.35E-05

0.78 (d)

F (1,34) = 0.08 (d)

< 0.01 (g) F(1,34) = 9.21 (g)
0.63 (d)

F (1,34) = 0.24 (d)

Reactive

1.32E-05 + 2.03E-06

3.85E-05 + 4.64E-06

1.50E-05 + 1.73E-06

3.54E-05 + 3.33E-06

< 0.01 (g) F(1,34) = 53.78 (g)

Amoeboid

3.77E-06 + 7.50E-07

1.24E-05 + 1.33E-06

3.80E-06 + 4.52E-07

9.94E-06 + 1.07E-07

< 0.01 (g) F(1,34) = 59.04 (g)

0.84 (d)

0.22 (d)

F(1,34) = 0.04 (d)

F(1,34) = 1.56 (d)

Table 4.1. Microglia density in CA1. Values represent the density of microglia in CA1 analyzed
as an ordinary two-way ANOVA with Sidak’s post-hoc tests. Values are represented as total count
per micron. WTNT n = 10; TGNT n = 9; WTTR n = 9; TGTR n = 10. Abbreviations: TgAD –
transgenic model of Alzheimer’s disease; DZ/DIB – Diazoxide / Dibenozoylmethane; WT – wildtype; g = genotype effect; d = DZ/DIB treatment effect; SEM = Standard Error of Mean; CA1 –
cornu ammonis 1
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Morphology

WT untreated

Tg-AD untreated

WT DZ/DIB Treated

Tg-AD DZ/DIB Treated

mean + SEM

mean + SEM

mean + SEM

mean + SEM

p-value

F(DFn, DFd)

< 0.01 (g) F (1,34) = 11.67 (g)
Total Microglia

2.67E-04 + 6.11E-06

3.17E-04 + 5.00E-06

2.70E-04 + 1.90E-05

3.00E-04 + 1.20E-05

Ramified

2.46E-04 + 6.70E-06

2.81E-04 + 1.55E-05

2.51E-04 + 5.76E-06

2.62E-04 + 8.90E-06

Reactive

Amoeboid

1.64E-05 + 2.43E-06

4.50E-06 + 6.52E-07

2.82E-05 + 3.49E-06

7.53E-06 + 9.02E-07

1.5E-05 + 2.23E-06

3.65E-06 + 5.97E-07

2.69E-05 + 1.96E-06

5.97E-06 + 5.21E-07

0.54 (d)

F (1,34) = 0.38 (d)

0.03 (g)

F(1,34) = 5.46 (g)

0.47 (d)

F(1,34) = 0.53 (d)

< 0.01 (g)

F(1,34) = 20.9 (g)

0.60 (d)

F(1,34) = 0.29 (d)

< 0.01 (g) F(1,34) = 15.38 (g)
0.09 (d)

F(1,34) = 3.13 (d)

Table 4.2. Microglia density in CA3. Values represent the density of microglia in CA3 analyzed
as an ordinary two-way ANOVA with Sidak’s post-hoc tests. Values are represented as total count
per micron. WTNT n = 10; TGNT n = 9; WTTR n = 9; TGTR n = 10. Abbreviations: TgAD –
transgenic model of Alzheimer’s disease; DZ/DIB – Diazoxide / Dibenozoylmethane; WT – wildtype; g = genotype effect; d = DZ/DIB treatment effect; SEM = Standard Error of Mean; CA3 –
cornu ammonis 3
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Morphology

WT untreated

Tg-AD untreated

WT DZ/DIB Treated

Tg-AD DZ/DIB Treated

mean + SEM

mean + SEM

mean + SEM

mean + SEM

p-value

F(DFn, DFd)

< 0.01 (g) F (1,34) = 15.15 (g)
Total Microglia

2.57E-04 + 4.62E-06

3.26E-04 + 2.72E-05

2.60E-04 + 4.00E-06

3.14E-04 + 1.61E-05

Ramified

2.35E-04 + 5.79E-06

2.63E-04 + 2.24E-05

2.28E-04 + 4.87E-06

2.55E-04 + 1.45E-05

Reactive

1.66E-05 + 2.50E-06

4.52E-05 + 5.12E-06

2.46E-05 + 2.47E-06

4.21E-05 + 4.03E-06

0.77 (d)

0.03 (g)

F(1,34) = 5.27 (g)

0.38 (d)

F(1,34) = 0.80 (d)

< 0.01 (g) F(1,34) = 39.25 (g)
0.51 (d)

Amoeboid

5.95E-06 + 1.17E-06

1.78E-05 + 2.22E-06

7.00E-06 + 5.54E-07

1.66E-05 + 2.10E-06

F (1,34) = 0.08 (d)

F(1,34) = 0.44 (d)

< 0.01 (g) F(1,34) = 41.01 (g)
0.97 (d)

F(1,34) < 0.01 (d)

Table 4.3. Microglia density in DG. Values represent the density of microglia in DG analyzed as
an ordinary two-way ANOVA with Sidak’s post-hoc tests. Values are represented as total count
per micron. WTNT n = 10; TGNT n = 9; WTTR n = 9; TGTR n = 10. Abbreviations: TgAD –
transgenic model of Alzheimer’s disease; DZ/DIB – Diazoxide / Dibenozoylmethane; WT – wildtype; g = genotype effect; d = DZ/DIB treatment effect; SEM = Standard Error of Mean; DG –
dentate gyrus
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Morphology

WT untreated

Tg-AD untreated

WT DZ/DIB Treated

Tg-AD DZ/DIB Treated

mean + SEM

mean + SEM

mean + SEM

mean + SEM

p-value

F(DFn, DFd)

< 0.01 (g) F (1,34) = 18.57 (g)
Total Microglia

2.40E-04 + 5.85E-06

3.01E-04 + 2.22E-05

2.31E-04 + 1.02E-05

2.97E-04 + 1.61E-05

Ramified

2.07E-04 + 6.63E-06

2.42E-04 + 2.00E-05

1.96E-04 + 1.33E-05

2.25E-04 + 1.33E-05

0.68 (d)

0.03 (g) F(1,34) = 5.09 (g)
0.32 (d)

Reactive

2.17E-05 + 2.46E-06

4.18E-05 + 3.13E-06

2.48E-05 + 4.19E-06

4.89E-05 + 4.71E-06

1.06E-0e + 2.02E-06

1.72E-05 + 2.39E-06

1.02E-05 + 1.79E-06

2.33E-05 + 2.84E-06

F (1,34) = 1.03 (d)

< 0.01 (g) F(1,34) = 35.10 (g)
0.18 (d)

Amoeboid

F (1,34) = 0.17 (d)

F(1,34) = 1.86 (d)

< 0.01 (g) F(1,34) = 18.23 (g)
0.23 (d)

F(1,34) = 1.51 (d)

Table 4.4. Microglia density in SB. Values represent the density of microglia in SB analyzed as
an ordinary two-way ANOVA with Sidak’s post-hoc tests. Values are represented as total count
per micron. WTNT n = 10; TGNT n = 9; WTTR n = 9; TGTR n = 10. Abbreviations: TgAD –
transgenic model of Alzheimer’s disease; DZ/DIB – Diazoxide / Dibenozoylmethane; WT – wildtype; g = genotype effect; d = DZ/DIB treatment effect; SEM = Standard Error of Mean; SB subiculum
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4.4.5 Age-dependent increases in APP levels were observed in 4-month versus 11-month TgAD rats and DZ/DIB treatment did not mitigate increases in APP levels.
Tg-AD rats were genetically designed to overexpress human APPsw and PS1 ∆E9, both
driven by the mouse prion promoter. We assessed the levels of full-length APP using the mouse
monoclonal antibody 22C11 which detects both human and rat APP (Figure 4.5A). A three-way
ANOVA analysis of APP levels across genotypes, treatment, and age revealed that Tg-AD rats,
irrespective of DZ/DIB treatment expressed higher levels of APP compared to age-matched WT
rats (Figure 4.5 B) F(1, 40) = 81.85; p < 0.001). An overall effect of age was observed, suggesting
that 11-months Tg-AD rats express higher APP protein levels (F(1, 40) = 6.184; p < 0.017) compared
to 4-month Tg-AD rats. Tukey’s post-hoc analysis showed there were genotype-specific post-hoc
differences between 4-month WT and 4-month Tg-AD untreated rats (q = 5.947, p < 0.01),
between 4-month WT DZ/DIB treated and 4-month Tg-AD DZ/DIB treated rats (q = 6.958, p <
0.01), between 11-month WT untreated and 11 month Tg-AD untreated rats (q = 7.510, p < 0.01),
and between 11-month WT DZ/DIB treated rats and 11-month Tg-AD DZ/DIB treated rats (q =
5.173, p = 0.02).
Ordinary two-way ANOVA analysis at 4-months revealed significant genotype differences
(F(1, 20) = 41.47; p < 0.001) in which Tg-AD AD rats had higher levels of APP regardless of drug
treatment (Figure 4.5 C). Post-hoc analysis showed differences between 4-month WT and 4-month
Tg-AD untreated rats (q = 5.936, p < 0.01), and between 4-month WT DZ/DIB treated rats and 4month Tg-AD DZ/DIB treated rats (q = 6.944, p < 0.01). At 11-months, significant genotype
differences (F(1, 20) = 40.38; p < 0.001) were observed, in which Tg-AD rats had higher levels of
APP regardless of drug treatment. Post-hoc analysis showed differences between 4-month WT and
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4-month Tg-AD untreated rats (q = 7.525, p < 0.01), and between 4-month WT DZ/DIB treated
rats and 4-month Tg-AD DZ/DIB treated rats (q = 5.184, p < 0.01) (Figure 4.5 D)
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N

APP / Actin Ratio
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Figure 4.5 – Tg-AD rats show increased levels of FL-APP in the hippocampus (A). FL-APP
(top panels) and actin levels (lower panels) were assessed by western blot analysis in whole left
hippocampal (combined ventral and dorsal) homogenates from WT and Tg-AD male and female
rats, both control and DZ/DIB treated at 4 and 11 months of age (n = 3 for all eight groups). Actin
served as the loading control. FL-APP and actin levels were semi-quantified by densitometry. Data
represent the percentage of the pixel ratio for FL-APP over actin for the comparison among all
eight groups. For this study males and females were combined, giving a total n = 6 for each of the
four treatment and age conditions. Values are means + SEM from 6 rats per genotype, treatment,
and age. Significance was determined first by overall three-way model ANOVA (B) to isolate
effects of age, drug treatment, and genotype, followed by individual two-way ANOVAs within
each respective age group (C for 4 months, D for 11 months). We found significant genotype
differences where Tg-AD rats expressed higher levels of FL-APP compared to WT rats,
irrespective of drug treatment or age. Age-specific analysis continued to show the genotype effect
on the Tg-AD rats. No DZ/DIB drug treatment effects were observed in FL-APP levels.
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4.4.6 Tg-AD rats did not exhibit significant differences in the protein levels of EGR2 and
caspase 3 irrespective of age or DZ/DIB treatment
A three-way ANOVA analysis of EGR2 levels across genotypes, treatment, and age
revealed a trend suggesting increased levels of EGR2 in DZ/DIB treated rats irrespective of
genotype or age F(1,

40)

= 3.836; p = 0.057). Tukey’s post-hoc analysis showed no post-hoc

differences. Ordinary two-way ANOVA analysis at four months revealed no significant effects of
treatment or genotype. At 11 months, we again observed a similar trend of increasing EGR2 levels
in DZ/DIB treated brains irrespective of genotype, although it was not significant (F(1, 20) = 3.422;
p = 0.079) No other post-hoc effects were observed.
A three-way ANOVA analysis of total caspase 3 levels across genotypes, treatment, and
age no significant differences in protein levels independent of genotype, age, or treatment. Tukey’s
post-hoc analysis also showed no post-hoc differences. Ordinary two-way ANOVA analysis at 4months and 11 months revealed no significant effects of treatment or genotype. No other post-hoc
effects were observed. The EGR2 and caspase 3 westerns are not shown because there are no
changes under all conditions.

4.4.7 DZ/DIB treatment attenuates age-dependent increases in eIF2-a protein levels detected
in Tg-AD AD rats.
eIF2-a is implicated in inhibiting overall protein synthesis, which could be detrimental to
neuronal cell viability in AD. I used a three-way ANOVA to assess total eIF2-a levels (Figure 4.6
A) in our DZ/DIB cohort and found an overall effect of drug treatment (Figure 4.6 B) F(1, 40) =
9.971; p < 0.01) regardless of age or genotype. No age or genotype effects were observed, nor
were there any post-hoc differences. Age-specific ordinary two way ANOVA analysis showed an
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effect of DZ/DIB drug treatment in reducing the levels of eIF2-a, regardless of age (F(1, 20) = 4.673;
p = 0.04 at 4 months, F(1, 20) = 5.306; p = 0.03 at 11 months) (Figure 4.6 C and D). No post-hoc
differences were observed at either time point, nor were there any genotype differences observed.
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Figure 4.6 – DZ/DIB treatment showed decreases in eIF2-a levels (A). eIF2-a (top panels) and
b-tubulin levels (lower panels) were assessed by western blotting in whole left hippocampal
(combined ventral and dorsal) homogenates from WT and Tg-AD male and female rats, both
untreated and DZ/DIB treated at 4 and 11 months of age (n = 3 for all eight groups). b-tubulin
served as the loading control. eIF2-a and tubulin levels were semi-quantified by densitometry.
Data represent the percentage of the pixel ratio for eIF2-a over tubulin for the comparison among
all eight groups. For this study males and females were combined, giving a total n = 6 for each of
the four treatment and age conditions. Values are means + SEM from 6 rats per genotype,
treatment, and age. Significance was determined first by overall three-way model ANOVA (B),
followed by individual two-way ANOVAs within each respective age group (C for 4 months, D
for 11 months). We saw DZ/DIB treatment reduce eIF2-a levels in the hippocampus of all DZ/DIB
treated rats irrespective of genotype or age.
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4.5 DISCUSSION
The buildup of Ab plaque and neurofibrillary tau tangles in the DG hilar subregion suggests
that the DG is more susceptible insults, possibly due to being more prone to development of the
senile plaques.101 This same susceptibility of the DG region to development of AD pathology
earlier than other hippocampal subregions explains why at 11 months of age, the neuronal loss
exhibited in Tg-AD rats is limited to the DG region, particularly in the granular cell layer,
consistent with prior reports.
eIF2-a is a subunit within the eIF2 initiation complex responsible for the regulation of
global and specific mRNA translation.124 Phosphorylation of eIF2-a by stress-activated kinases
(such as pERK, HIR and KPR) prevents nucleotide exchange and sequesters eIF2B, limiting the
availability of eIF2-a/GDP complex, leading to decreases in translation. DZ/DIB treatment
induced a decrease in the levels of eIF2-a protein in the overall hippocampus, indicating that there
is reduced likelihood for premature translational depression, consistent with prior DIB treatment
investigations.124
Formation of neurofibrillary tau tangles are suggestive of neuronal cell stress due to
disruptions to microtubule structure caused by hyperphosphorylation of tau9. Since the DZ/DIB
treatment effects on reducing PHF1 immunostaining extended past the DG hilar region,
encompassing the entire DG region, as well as CA3 it is possible that lowering eIF2-a levels with
DZ/DIB treatment may make neuronal cells less prone to the formation of PHFs, the precursors to
tau tangles, in the short-term due to continued neuronal cell protein synthesis.
The original studies showed caspase 3 cleavage is not observed in the Tg-AD rats until 26
months of age. In addition, in my studies I did not detect significant changes in full-length caspase
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3 levels. Thus is it likely that early apoptotic signs (at least in neurons) do not occur at 11 months
of age in the Tg-AD rats.
EGR2 was found to be required for the upregulation of M1 and M2 microglia phenotype
specific markers (IFNg, LPS, TNF-a, and IL-6 for M1; IL-4, and IL-13 for M2) in response to
stimuli, with downregulation being correlated with an unresponsiveness of M1 microglia to further
stimulation125. In addition, EGR2 negatively regulates T and B cell activation and production of
pro-inflammatory cytokines through induction of the suppressor of cytokine production signaling
(SOCS) molecules 1 and 3.126 Based on these findings, my results showing a trend in favor of
increased EGR2 in DZ/DIB treated rats, could support a DZ/DIB dependent increase in plasticity
for M1 and M2 microglia polarization, which would need to be further investigated.
DZ increases intracellular potassium levels and conversely reduces intracellular calcium
levels, while DIB has a host of effects on signaling pathways involved in cancer, mitigating
inflammation and cellular stress, and neuroprotection.123 My investigations on the therapeutic
potential of the combination DZ/DIB treatment showed reductions in Ab plaque and tau PHF1
loads. This is consistent with prior investigations using the individual drugs. DZ/DIB treatment
could be maintaining protein translation and showing some neuroprotective potential due to
reductions in eIF2a expression upon treatment. Overall, my results suggest that DZ/DIB treatment
holds therapeutic potential to treat AD pathology.
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Figure 4.7: Possible DZ/DIB mechanism for attenuating AD pathology: DZ/DIB combined
treatment showed a trend of increasing EGR2 levels, previously shown to activate the suppressor
of cytokine production signaling (SOCS) molecules 1 and 3. Upregulation of EGR2 also influences
the polarization of M1 and M2 microglia, rendering M1 microglia responsive to secreted
cytokines. I also see an effect of dual treatment on eIF2-a, shown to inhibit neuronal cell
translation. The decrease in eIF2-a levels helps maintain translation, and therefore prevents
apoptosis.
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AD is a serious problem for our aging population. With current therapeutics failing to halt
disease progression, investigations should focus on novel therapeutic approaches towards AD.1 106
While the risk factors for AD range from genetic to environmental factors, no one set of factors is
sufficient to explain who definitively develop AD. The obscurity behind which combination of
risk factors will ensure an individual will suffer from AD has stumbled researchers in their attempts
to develop therapeutics against AD.127
One of the problems with the currently proposed AD therapeutics is the single-targeted
approach investigators have used for decades concentrating on removing the Ab plaques or
neurofibrillary tau tangles, hoping it will be sufficient to prevent further AD progression.
Considering the complexity of AD and the timeline for drug design, testing, and eventually FDA
approval spanning many years from design to execution, a treatment failure is a major setback for
investigations.
My studies were based on our collaborator Dr. Lei Xie’s screening of previously FDAapproved drugs designed for the treatment of other disorders with pathologies similarities to AD
and repurposing them as possible AD therapeutics utilizing a bioinformatics approach.73 This
bioinformatics approach allows for the fast-tracking of any promising therapeutic to clinical trials
since possible side effects have been fully documented.120
My studies focused on three compounds: the phosphodiesterase inhibitor IBU, the
potassium channel activator DZ, and the anticancer drug DIB as promising therapeutics. I assessed
the potential efficacy of these drugs on the TgF-344 AD rat model that exhibits the AD hallmarks
more in line with the progression of human AD and considers aging as a risk factor. Since
successes in other neurodegenerative disorders are observed when therapeutic intervention occurs
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early into the disease state, I started IBU treatment at five months of age, and DZ/DIB combination
treatment at 52 days of age, prior to development of Ab plaques.
A.

IBU treatment improved the following AD conditions exhibited by the 11-month-

old Tg-AD rats compared to age-matched wild-type control rats
1. Spatial memory deficits
2. Ab plaque and neurofibrillary tau tangle burden in the hippocampal DG region.
The DG effects could be partially explained by the increased sensitivity of this hippocampal region
to the accumulation of Ab and hyperphosphorylated tau.80
3. Ratio of amoeboid to ramified microglia, indicating that there was suppression of
microglial cell activation in response to the plaques. Considering that there was a reduction in the
Ab plaque burden, it is possible that the two findings are connected: fewer plaques to clear – lower
extent of microglia response.
4. Gene expression involved in TLR signaling and the ubiquitin-proteasome system.
Of particular interest were the changes in mRNA expression levels for (1) IRAK3 (also known as
IRAK-M), a protein inhibitor of TLR signaling, (2) TRAF6, the ubiquitin ligase responsible for
initiating polyubiquitination of IRAK1 and the phosphorylation of IRAK1’s downstream target,
TAK1, (3) the adaptor protein Tollip, which initially prevents IRAK1 autophosphorylation in the
absence of a stimulus, and (4) pellino1 (a ubiquitin ligase) which can be used for assessing IRAK1
catalytic activity
These findings suggest that although IRAK1 mRNA levels are not significantly altered
with IBU treatment, it is possible that the effect IBU is having on the genetic level with
downstream IRAK1-associated proteins could be attributed to protein-drug interactions between
IRAK1 and IBU.
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B.

DZ/DIB treatment: Since the progression of AD entails many biological changes

with respect to signaling pathways, it is possible that a single drug treatment, irrespective of how
promising its effect on addressing AD symptoms, may be insufficient to significantly halt disease
progression.119 While IBU may act on the TLR pathway to reduce inflammation, this is far from
the only mechanism in which inflammation can lead to neuronal loss.128 For this reason, we used
a combination DZ/DIB treatment to target multiple signaling pathways involved in apoptosis and
to evaluate the effects of treatment on AD pathology.

DZ/DIB treatment improved the following AD conditions exhibited by the 11-month-old Tg-AD
rats.
1. Ab plaque and neurofibrillary tau tangles in the hippocampal DG hilar region and
in the DG and CA3 regions, respectively
2. Levels of eIF2a, a protein previously shown to abruptly terminate protein synthesis
in neurons, causing cell death.
3. No significant effect on reducing gliosis and neuronal loss were detected by
DZ/DIB treatment.
I also detected changes in the expression of two genes, EGR2 and HIST1H2AA at 4 months
of age in Tg-AD rats compared to WT controls, suggesting that these genes could be considered
novel early biomarkers of AD prior to the development of other conventional AD hallmarks.
Finally, upon an extensive literature search, I discussed the discrepancy between the human
and mouse genome, in terms of the TLR signaling pathway. This is important because comparing
different TLR distribution and levels in mouse and human brains, could improve the predicted
efficacy of drugs to treat neuroinflammation in AD.
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In conclusion, our findings suggest that the early intervention approach against AD shows
therapeutic promise in mitigating the early signs of disease progression. Addressing
neuroinflammation and apoptotic signaling pathways is also a viable strategy towards the design
and repurposing of therapeutics due to their effects on maintaining cell viability, something that is
not observed in previous AD drugs that have only focused on clearing the senile plaques or tangles,
without addressing neuronal loss that is correlated with cognitive decline.
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The failure to develop efficacious treatments for Alzheimer’s disease (AD) can be
attributed to several factors including (1) the multifactorial nature of the disease, (2) animal models
that have poor translational potential, and (3) utilization of one drug-one target therapeutic design.
However, our lab identified ibudilast (IBU) as a promising therapeutic to remediate AD pathology.
My studies identified IBU and combined DZ/DIB as promising therapeutics to remediate AD
pathology.
While both IBU and DZ/DIB show promise as AD therapeutics by differing mechanisms
(reducing inflammation in IBU and preventing neurodegeneration for DZ/DIB), both mechanisms
share a common problem; their therapeutic potential was evaluated in large part in a Tg-AD rat
model for AD, leaving the remaining issue how to translate the observed results for human
relevance.
Prior to investing resources towards methods such as the growing of organoids or the use
of induced pluripotent stem cells (iPSCs), it is important to obtain additional data supporting the
beneficial IBU, DZ, and DIB effects on signal transduction pathways.
With respect to IBU, I propose the following approaches to further investigate TLR
signaling and its outputs.

1: Determine the structural changes IRAK1 undergoes in the presence of IBU. I hypothesize
that IBU will bind IRAK1 within the ATP binding pocket. To that end, IRAK1 would need to be
purified from human cell lysates (glial cells and neurons) and incubated with different
concentrations of IBU to assess changes in temperature-induced fluorescence changes using
microscale thermophoresis (MST). Using observed fluorescence changes, the degree of
conformational change induced by IBU docking IRAK1 can be determined. The location of IBU

101

docking can be explored by using 2-dimensional NMR and confirming the docking by docking a
known IRAK1 inhibitor that targets the ATP binding pocket.
Aside from merely observing the structural dynamics of the IBU/IRAK1 interaction, this
set of experiments proves useful in providing data to generate other compounds that are similar in
structure to IBU to observe their effects on the TLR pathway in cells.

2: Uncover the mechanistic impact of IBU on the TLR Pathway. I hypothesize that IBU
inhibits the TLR cascade likely due to stabilization of an IRAK1 complex with an adaptor protein.
IRAK1 phosphorylation promotes the binding of IRAK1 to TRAF6, allowing the complex to
phosphorylate the downstream protein TAK1 and continue the signaling cascade. To do so,
IRAK1 must first dissociate from IRAK4, a mechanistic step that occurs upon IRAK1
autophosphorylation due to the structural perturbations that occur within the myddosome.
My preliminary data showed that IBU treatment reduces the levels of IL-6 secretion from
human microglial HMC3 cells (Figure 6.1). I treated HMC3 cells with a combination of the three
drugs TAK243, IL-1b, and IBU, in the following sequence: On the day of treatment, media was
changed and cells were first treated with 200nM TAK-243, 30 minutes later cells were stimulated
with 10ng/mL IL-1b, and finally 30 minutes later cells were treated with 50µM IBU. Untreated
cells were instead treated with DMSO. EMEM media was used for IL-1b control conditions.
Considering the relationship between TLR signaling and the ubiquitin/proteasome pathway, I
decided to investigate the effect of inhibiting ubiquitination on cytokine secretion. I treated HMC3
cells short-term with 200nM TAK-243 based on manufacturer’s suggestion.129 As an inhibitor of
the E1 ubiquitin activating enzyme, TAK-243 reduces the formation of polyubiquitin chains,
which could also act as an inhibitor of TRAF6, an E3 ubiquitin ligase.130 With reduced TRAF6
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activity, I expected to see a reduction of IL-6 levels.
IL-1b is secreted by active macrophages as a pro-protein, where it is cleaved by caspase 1
and plays an important role in inflammation, cell proliferation, differentiation, and apoptosis.131
Binding TLR4 as a DAMP, IL-1b activates the pro-inflammatory response and promotes cytokine
secretion, which is important under stress conditions. When the stress is removed, IL-1b
production ceases, and microglia return to a resting-state where only basal levels of proinflammatory mediators are produced. In AD, the constant presence of extracellular stresses
maintain microglia in a chronic pro-inflammatory state, therefore maintaining TLR signaling
active in the long-term.132 133
Statistical analysis of my preliminary data with an overall three-way ANOVA with
Tukey’s post-hoc analysis across the three treatments IL-1b, TAK-243, and IBU showed that there
are significant changes in IL-6 secretion under different conditions (Table 6.1, 6.2 and 6.3).
To address the IBU-induced glial suppression properties, it would also be important to
measure anti-inflammatory cytokine levels, particularly IL-4, IL-10, and IL-13, considering that
I detected decreases in IL-6 (pro-inflammatory cytokine) levels with treatment.
Together these experiments will potentially identify a mechanism by which IBU affectss
IRAK1 function.
RNA sequencing analysis from IBU-treated versus IBU-untreated rat hippocampal tissue
showed a sex-independent increase in gene expression for IRAK-M, the inhibitor of TLR
signaling, and a sex-dependent change in the mRNA levels for Tollip, an IRAK1 adaptor protein.
These findings together with the in silico prediction that IBU targets IRAK1, support that this
TLR signaling pathway should be investigated further to uncover the true consequences of IRAK1
docking by IBU (Figure 6.2.). To this end, I propose co-immunoprecipitation studies to determine
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which IRAK1 protein complexes are influenced by IBU, such as the IRAK1-Tollip, IRAK2IRAK4, and/or IRAK1-TRAF6. The impact of the short half-life of IRAK1, and IRAK2
regulation of IRAK1 degradation on TLR signaling need to be considered. In conclusion, this
information will optimize the development of therapeutics targeting TLR signaling to treat
neurodegenerative disorders.

3.

Investigate the effect of the combination treatment on previously established DZ and
DIB specific targets.
DZ treatment in previous studies with rats activated BCL-2 along with BAX inhibition,

contributing to inhibition of caspase-dependent apoptosis. As a potassium channel activator, DZ
has also shown promise in reducing oxidative stress and attenuating neurodegeneration.
With respect to DIB, eIF2-a contributes to ER stress kinases (such as pERK, HIR and
KPR), prevents nucleotide exchange and sequesters eIF2B, limiting the availability of eIF2a/GDP complex, leading to decreases in protein synthesis. Considering the central theme of
inhibition of apoptosis, a plausible approach to continue this study would be to:
A.

Utilize human cell models to study DZ and DIB combination treatment effects on

eIF2-a and BCL-2 signaling. Considering both pathways converge on apoptosis, it is possible a
combination treatment would block various apoptotic mechanisms, leading to increased cell
viability. To that end, we would need to culture neuronal and glial cells to measure cell viability
with combination treatment, followed by western blot analysis for BCL, BAX, the stress kinases
HIR and KPR, and the various subunits of eIF2, along with eIF2B. Considering eIF2a is a subunit
of the eIF2 complex, it would prove beneficial to also perform co-immunoprecipitation studies,
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particularly to study the complex formed with GDP in the presence of the stress kinases and their
consequences on caspase activation.
B.

Use human cell models to measure the levels of reactive oxygen species, nitric

oxide production, and cytokines. Since DZ/DIB treatment in my rats showed a trend favoring
increased EGR2 levels and its effect on regulating NF-kB independent of TLR signaling, it is
possible that dual treatment will have an effect on cytokine secretion. Similar to the IBU studies,
we would measure both pro- and anti-inflammatory cytokine secretion in glial cells using ELISAs.
To address the production of reactive oxygen species, the Greiss reagent kit could be used to
measure levels of nitric oxide and perform western blot analysis to measure the levels of induced
Nitric Oxide synthase (iNOS) following drug treatment. CellROX, MitoSOX, Imagee-iT
Lipidperoxidation, and ThiolTracker Violet kits could be used to measure levels of general ROS,
lipid peroxidation, mitochondrial ROS, and glutathione.
C.

Determining NFkB levels by western blot would involve assessing cytoplasmic

and nuclear fraction levels of the protein, and a secondary co-IP experiment, measuring the level
of bound NF-kB to IkB. IkB is normally bound to NFkB, and upon phosphorylation by the IKK
complex, IkB loses its affinity for NFkB and is degraded by the ubiquitin/proteasome pathway.
Following nuclear translocation, NFkB promotes transcription and translation of IkB in addition
to the cytokines, serving as a negative feedback loop to prevent constitutive activation.
My expected outcomes are that these studies will highlight the therapeutic potential of IBU,
DZ, and DIB against AD progression, while concurrently addressing mechanistic changes induced
by drug treatment.
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Figure 6.1. Ibudilast treatment reduced IL-6 secretion. Cells were pre-treated for 60 minutes
with IBU, following pre-treatment with a combination of TAK-243 and IL-1b. On the day of
treatment, media was changed, and cells were first treated with 200nM TAK-243. 30 minutes later,
cells were stimulated with 10ng/mL IL-1b. 30 minutes later, cells were treated with 50µM IBU.
Untreated cells were instead treated with DMSO (EMEM media for IL-1b control conditions).
Cells were harvested 60 minutes after IBU treatment. (A) Three-way ANOVA analysis
considering IBU, TAK-243, and IL-1b treatments shows an increase in IL-6 secretion when cells
are stimulated with IL-1b. Pre-treatment with TAK-243 followed by IBU induced a decrease in
IL-6 secretion when microglia cells are stimulated with IL-1b. (B) Ordinary two-way ANOVA
analysis of cells not treated with TAK-243 still show the same increase in IL-6 secretion when
HMC3 cells are in the presence of IL-1b. IBU treatment without TAK-243 does not decrease IL6 secretion. (C) Two-way ANOVA analysis shows IBU treatment reduces IL-6 secretion when
cells are stimulated with IL-1b in the presence of TAK-243, or when just pre-treated with TAK243 in the absence of IL-1b. (n = 3 for all conditions).
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Source of Variation

F (DFn, DFd)

p-value

TAK-243 treatment

F (1, 16) = 4.552

0.049

IL-1b treatment

F (1, 16) = 1776

< 0.01

IBU treatment

F (1, 16) = 0.2446

0.628

TAK-243 x IL-1b treatment

F (1, 16) = 29.94

< 0.01

TAK-243 x IBU treatment

F (1, 16) = 59.81

< 0.01

IL-1b x IBU treatment

F (1, 16) = 4.965

0.041

TAK-243 x IL-1b x IBU treatment

F (1, 16) = 10.75

< 0.01

Table 6.1 – Three-way ANOVA analysis of IL-6 secretion across various treatment
conditions. Three-way ANOVA analysis of IL-6 secretion across samples treated with a
combination of the following treatments: TAK-243, IL-1b, and IBU, as shown in figure 6.1.A.
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Source of Variation

F (DFn, DFd)

p-value

IL-1b treatment

F (1, 8) = 426.7

< 0.01

IBU treatment

F (1, 8) = 16.63

< 0.01

Tukey’s Multiple Comparison Test

q-value

p-value

Condition 1

Condition 2

DMSO / DMSO

DMSO / IBU

7.181

< 0.01

DMSO / DMSO

DMSO / DMSO + IL-1b

23.76

< 0.01

DMSO / IBU

DMSO / IBU + IL-1b

17.56

< 0.01

DMSO / DMSO + IL-1b

DMSO / IBU + IL-1b

0.9762

0.898

Table 6.2 – Two-Way ANOVA analysis of IL-6 secretion - Ordinary two-way ANOVA analysis
of IL-6 secretion with and without IL-1b and IBU (shown in figure 6.1B). Samples were not pretreated with TAK-243. The top table shows overall ANOVA effects. The bottom table shows the
multiple comparison tests.
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Source of Variation

F (DFn, DFd)

p-value

IL-1b treatment

F (1, 8) = 2669

< 0.01

IBU treatment

F (1, 8) = 79.72

< 0.01

Tukey’s Multiple Comparison Test

q-value

p-value

Condition 1

Condition 2

TAK-243 / DMSO

TAK-243 / IBU

10.07

< 0.01

TAK-243 / DMSO

TAK-243 / DMSO + IL-1b

50.52

< 0.01

TAK-243 / IBU

TAK-243 / IBU + IL-1b

52.80

< 0.01

TAK-243 / DMSO + IL-1b

TAK-243 / IBU + IL-1b

7.789

< 0.01

Table 6.3 – Two-Way ANOVA analysis of IL-6 secretion in TAK-243 treated samplesOrdinary two-way ANOVA analysis of IL-6 secretion in samples pre-treated with TAK-243, with
and without IL-1b and IBU (shown in figure 6.1C). The top table shows overall ANOVA effects.
The bottom table shows the multiple comparison tests.

110

Figure 6.2. Proposed mechanism for IBU (left) and TAK-243 (right) inhibition of TLR
signaling. IBU is predicted to target IRAK1 using an in silico approach. My preliminary studies
showed that IBU/TAK-243 treatment reduces IL-6 levels after HMC3 cells are stimulated with IL1b. These findings support mechanisms by which IBU/TAK-243 affect the TLR signaling, as
shown in the above scheme.
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